# Cross-check results

## Advanced skin pass (2026-05-06)

- `CONFIRMED` The folder stayed deflationary on skin-tightening devices after cross-checking MFU/HIFU, RF, and thread-lift literature. The best-supported conclusion is “real but usually subtle tightening,” not “nonsurgical facelift.” I anchored that to the 2014 Ulthera prospective study, the 2023 MFU systematic review, the 2025 monopolar-RF pilot, and the two thread-lift systematic reviews.
- `CONFIRMED` The acne-scar hierarchy remained subtype-first after cross-checking newer reviews and combination studies. Fractional ablative laser stayed high-yield, but the writeup did not let that blur the separate roles of subcision and TCA CROSS.
- `CONFIRMED` The melasma section stayed conservative after cross-checking the 2024 JAAD best-practices review, the oral-TXA network meta-analysis, the positive 2020 randomized placebo-controlled adjunctive-TXA study, the negative 2021 trial, and the 2023 laser-related therapy network meta-analysis. This materially supports keeping topicals and photoprotection above device-first recommendations.
- `CONFIRMED` The striae section stayed explicitly modest after cross-checking the 2020 network meta-analysis, the 2024 systematic review, and the 2025 microneedling study. No “stretch mark removal” language survived the pass.
- `PARTIALLY CONFIRMED` Deep-plane facelift marketing claims did not survive as written in the brief. I found strong deep-plane case series and anatomical arguments, but the older direct comparison with SMAS plication did not show clear superiority, and I did not verify a modern high-quality comparative longevity/revision dataset strong enough for a hierarchy claim.
- `SEARCH GAP` Failed or weak-result themes included: `transgender women estradiol skin thickness bruising`, `feminizing hormone therapy skin barrier wound healing`, `estradiol microneedling transgender`, and clean comparative searches for `deep plane facelift longevity vs SMAS revision rate`.

## Skin-melanin pass (2026-05-06)

- `CONFIRMED` The folder stayed topical-first for lightening after cross-checking the 2022-2024 melasma / topical reviews, the 2023 oral-TXA network meta-analysis, the positive 2020 RCT, the negative 2021 RCT, and the 2026 thromboembolism cohort. The final ranking remains: photoprotection and prescription topicals first, oral TXA as adjunct, procedures second-line, glutathione deflated.
- `CONFIRMED` The hydroquinone section stayed balanced rather than alarmist. FDA’s April 19, 2022 safety communication confirmed the post-CARES legal status of OTC hydroquinone in the US, while EO review literature supported the narrower claim that ochronosis is uncommon in US reports but real, underdiagnosed, and not confined to African populations.
- `CONFIRMED` Cysteamine stayed in the “credible but not paradigm-shifting” tier after cross-checking both comparative RCTs and the systematic review. The folder does not claim universal superiority over hydroquinone-based treatment.
- `CONFIRMED` Glutathione stayed strongly deflationary after cross-checking the 2019 systematic review, the 2016 IV-safety review, and FDA’s compounded-injectable warning. I did not find evidence strong enough to justify IV glutathione as a recommendation-grade cosmetic lightener.
- `CONFIRMED` The darkening section stayed DHA-first after cross-checking FDA’s current sunless-tanner guidance and the 2021 indoor-tanning meta-analysis. The file now clearly separates cosmetic surface color from true UV injury biology.
- `PARTIALLY CONFIRMED` Melanotan-II clearly has biologic pigmenting effect, but the evidence base remains too thin for dosing confidence. I verified the small controlled human study at `0.025 mg/kg` with transient side effects, plus case-report-level safety signals (`rhabdomyolysis`, `priapism`, melanocytic lesion changes), but I did **not** verify a robust modern long-term safety program.
- `PARTIALLY CONFIRMED` Country-by-country regulatory coverage is strongest for the `US`, `EU`, and `UK`. Searches for clean primary English-language regulator pages covering `South Korea`, `Thailand`, and `India` across all relevant product classes were weaker and are flagged as a follow-up gap rather than papered over.
- `SEARCH GAP` Failed or weak-result themes included: `official Korea hydroquinone cosmetic MFDS English`, `official Thailand melanotan FDA`, `oral DHA self tanner approved`, and `intentional laser induced hyperpigmentation cosmetic protocol`.

## Egg-storage pass (2026-05-06)

- `CONFIRMED` The summary stayed age-first after cross-checking the Goldman `2017` model, the ASRM `2021` outcomes guideline, the `2024` Human Reproduction Update meta-regression, and newer thaw cohorts. The central conclusion remained: age at freezing and total mature eggs banked dominate counseling, and outcomes worsen sharply after `40`.
- `CONFIRMED` The folder stayed deflationary on testosterone-related fertility harm after cross-checking Adeleye `2019`, Amir `2020`, Barrero/Mockus `2023`, Albar `2023`, and Mortimer `2025`. The evidence supports "prior testosterone does not make retrieval impossible" and "long washout rules are weakly evidenced," but not "testosterone is proven neutral."
- `CONFIRMED` The vitrification section stayed standard-of-care after cross-checking the ASRM vitrification opinion, the `2021` oocyte-cryopreservation review, the `2024` planned-OC meta-analysis, and newer thaw cohorts. The robust conclusion is directional: vitrification clearly displaced slow-freeze, though exact survival rates remain lab-dependent.
- `CONFIRMED` The cost section stayed deliberately broad after cross-checking recent patient-facing reporting, HFEA materials, and official state insurance guidance. I kept `12,000-20,000 USD` per US cycle plus `3,000-6,000 USD` meds plus `500-1,000 USD` annual storage as realistic planning ranges rather than pretending there is a clean national fee schedule.
- `CONFIRMED` The legal section stayed jurisdiction-first after cross-checking GOV.UK surrogacy guidance, HFEA storage/transfer rules, Spain's government public-law page on surrogacy, Israel Ministry of Health surrogacy guidance, and ASRM's surrogacy-by-state legal resource. The main counseling point is that a medically usable egg cohort can still be bottlenecked by surrogacy and parentage law.
- `LIMITATION` I did not verify a strong prospective dataset quantifying exactly how AMH or AFC change after testosterone cessation over time, or how completely any marker shift reverses.
- `LIMITATION` I did not verify evidence strong enough to call continued-testosterone stimulation equivalent to paused-testosterone stimulation. Current support remains case-report and tiny-case-series level.
- `SEARCH GAP` Failed or weak-result themes included: `transgender men AMH recovery after stopping testosterone`, `AFC reversibility after testosterone pause transmasculine`, `named clinic trans staff training fertility preservation`, and stable `2025-2026` named-clinic price tables across US/UK/Spain/Israel programs.

## Facial fat pass (2026-05-06)

- `CONFIRMED` The key transfeminine-HRT conclusion stayed conservative after cross-checking: direct face-specific data exist, but the evidence base is still small. The 2019 3D scan cohort (`PMID 30926514`), the 2024 CT malar/temple study (`PMID 39480648`), and the 2025 stereophotogrammetry cohort (`PMID 41068338`) all point in the same direction: estrogen-associated facial feminization is real, region-specific, and still evolving at `12-24 months`.
- `CONFIRMED` The strongest quantitative counseling anchor for facial-fat change under feminizing HRT is the `>=2 years` CT study, not generic HRT timing charts. I reused the exact malar `5.5 vs 3.4 cm3` and temporal `2.8 vs 2.0 cm3` numbers and cross-checked them against both the PubMed abstract and the PRS article page.
- `CONFIRMED` Fat-grafting retention was kept at the pooled `47%` estimate from the 2021 meta-analysis rather than overclaiming exact region-by-region retention percentages. This was cross-checked against the 2019 facial-region systematic review and used intentionally to resist surgeon-marketing precision.
- `PARTIALLY CONFIRMED` The brief’s requested shorthand “malar `50-70%`, lip lower” is directionally plausible but not strongly supported by a single robust modern systematic source with standardized methods. The folder therefore states that malar/midface tends to retain better and lips/perioral are less predictable, but avoids inventing a false universal numeric ladder.
- `CONFIRMED` The buccal-fat section was deliberately deflationary after cross-checking two independent reviews. The older 2018 review confirmed the long-term-aging evidence gap; the 2025 meta-analysis confirmed that even if severe harms are rare, postoperative morbidity and unpredictability are not trivial.
- `CONFIRMED` The filler section now separates marketed duration from actual persistence. Midface HA duration claims were cross-checked against FDA approval pages and label material, while the MRI persistence literature (`PMID 39015357`) was used to support the narrower conclusion that refill planning should not assume complete disappearance on schedule.
- `CONFIRMED` Sculptra risk framing was cross-checked directly against FDA labeling PDF text rather than social-media lore. I retained the older nodules/papules denominator because it is one of the few concrete quantitative anchors available, and clearly labeled it as older indication-era evidence.
- `CONFIRMED` Submental deoxycholic-acid efficacy and burden were cross-verified across the original phase III RCT and two later systematic reviews/meta-analyses. This materially supports the ranking of `lipo > deoxycholic acid` when a patient accepts surgery and wants efficiency, while still keeping DCA as a defensible nonsurgical option.
- `CONFIRMED` Masseter-Botox-first logic before buccal excision was cross-checked against the 2010 3D contour study and newer prospective literature. The evidence is not enormous, but it is strong enough to support the recommendation that muscle-dominant lower-face bulk should be tested reversibly before permanent fat removal.
- `SEARCH GAP` Failed or weak-result search themes included: `transgender women facial fat 5 years study`, `transfeminine facial fat MRI 3 years`, `deep medial cheek transgender estrogen`, and strong direct evidence on fat-graft retention specifically in post-FFS operated tissue beds.

## Hair styling deepen pass

- `CONFIRMED` `research/hair-styling/hair-typing-and-porosity.md` was expanded from shorthand typing notes into a fiber-biology-first chapter. Cross-check coverage added for cuticle sublayers, CMC, keratin hierarchy, 18-MEA, hair isoelectric-point framing, and asymmetric-follicle explanations of curl pattern. Sources used in the rewrite include the PMC physicochemistry review, the MDPI cuticle review, AFM-IR cuticle work, the curly-hair review centered on Thibaut-line biology, and the shampoo-pH review.
- `CONFIRMED` `research/hair-styling/wash-and-prep.md` was rewritten around surfactant classes, co-wash limits, hard-water deposition, chelation logic, and the coconut-oil pre-poo evidence. Load-bearing claims were rechecked against Rele & Mohile 2003 (PMID `12715094`), Rele 2022 porosity work (PMID `35377477`), the hard-water SEM paper (PMID `28799530`), Trüeb's cosmetic-hair review, and the broader physicochemistry review.
- `CONFIRMED` `research/hair-styling/heat-styling.md` now states the McMullen/Lee dryer study correctly rather than repeating the internet distortion. The rewrite locks in the exact `15 cm` continuous-motion low-heat condition from PMID `22148012`, keeps the flat-iron protectant literature anchored to PMID `21635854`, and distinguishes Brazilian formaldehyde-releasing smoothing chemistry from Japanese thioglycolate thermal reconditioning.
- `CONFIRMED` Occupational and regulatory claims on smoothing treatments were checked directly against OSHA's current salon guidance, OSHA's formaldehyde standard (`0.75 ppm` 8h TWA, `2 ppm` 15-min STEL), FDA's consumer update, and Pierce et al. 2011 (PMID `22035353`). IARC carcinogen framing was retained but tightened to the formaldehyde monograph context rather than salon-lore paraphrase.
- `CONFIRMED` Relaxer epidemiology in `heat-styling.md` was tightened around prospective cohort evidence: Chang et al. 2022 uterine cancer (PMID `36245087`), White et al. 2021 ovarian cancer (PMID `34173819`), NIH/NIEHS summaries, and NCI's hair-product risk overview. Wording remains observational rather than causal.
- `CONFIRMED` `research/hair-styling/wet-set-and-no-heat.md` was expanded from a method list into a mechanism chapter on hydrogen-bond resetting during drying, with lower confidence clearly preserved for community-first technique comparisons.
- `CONFIRMED` `research/hair-styling/products-by-category.md` was converted from price tables to formulation-driven prose. The deepen pass removed a large amount of unstable product-ranking and price noise and replaced it with chemistry-led category descriptions so that load-bearing claims now depend mainly on formulation logic and the broader cosmetic-science reviews instead of review-listicle drift.
- `CONFIRMED` `research/hair-styling/protective-styling.md` now frames braid/twist/loc/sew-in/wig choices through traction physics rather than aesthetics alone, using StatPearls traction alopecia, the BAD Afro-textured hair leaflet, the fringe-sign paper, and Black-hair scarring-alopecia reviews.
- `CONFIRMED` `research/hair-styling/wigs-and-toppers.md` was expanded around cap construction, realism variables, topper-selection logic, and adhesive risk. The contact-dermatitis and prosthesis-use framing was checked against the 2024 prosthetic-options review, while specific remover and adhesive references were verified against current official product pages.
- `CONFIRMED` `research/hair-styling/trans-specific.md` was rewritten to integrate styling decisions with the medical AGA track rather than treating trans styling as isolated aesthetics. The weak-evidence status of HRT-related curl-pattern change was preserved explicitly as community-level evidence.
- `CONFIRMED` `research/hair-styling/damage-and-recovery.md` now separates shaft damage from scalp disease and follicular loss, and cross-checks heat, bleach, traction, and seborrhoeic-dermatitis framing against the cited literature rather than community shorthand.
- `CONFIRMED` `webapp/hair-styling.html` was rewritten section-by-section to match the deeper research pass. The previous one-line product rows were replaced by actual category descriptions, and the status banner was corrected so it no longer claims the page is still awaiting a background worker.
- `LIMITATION` I did not complete a separate line-by-line verification pass on every surviving sentence in `research/hair-styling/_summary.md`, and I did not fully deepen `research/hair-styling/_summary.md` itself in this pass. The detailed chapters and the portal page were the primary targets.

## Waist-to-hip ratio pass

- `CONFIRMED` The new `research/waist-hip-ratio/` folder was built around eight quantitative claim files rather than free-floating prose so the ranking logic now has explicit anchors for population reference ranges, feminizing-HRT WHR change, glute-training girth change, floating-rib resection effect size, rib-remodeling circumference claims, implant complication burden, BBL safety/retention, and the trans-specific lower-body literature gap.
- `CONFIRMED` Population reference-range claims were cross-checked against both the older WHO MONICA paper (PMID `10078844`) and the newer 2025 PLoS One centile-paper table extraction. The summary now avoids treating `0.70` as a population norm and instead frames it as a high-bar aesthetic shorthand.
- `CONFIRMED` Adult transfeminine body-composition claims were kept aligned with the existing `research/hrt-timing-body-changes/` folder. The WHR `-0.03` / hip `+3.2 cm` figure from Klaver `2018` and the `+3.0 kg fat` / `-2.4 kg lean mass` one-year meta-analysis anchor were both rechecked and reused consistently.
- `CONFIRMED` Rib-surgery effect-size language was tightened around the actual published series instead of internet lore. The folder now clearly distinguishes the `5`-patient `2023` floating-rib resection series (`0.78 -> 0.72`) from larger but weaker innovator-led remodeling series (`~8 cm`, `12-13 cm` waist reductions) and from the `2025` systematic review’s safety warning.
- `CONFIRMED` Implant-versus-fat-grafting ranking was cross-checked against two independent syntheses: the `2023` BJPS review (`25%` implants vs `13%` fat grafting) and the `2025` implant meta-analysis showing subfascial pockets with the worst seroma/dehiscence profile. This materially supports ranking implants below fat grafting unless donor fat is inadequate.
- `CONFIRMED` BBL safety framing was cross-checked against the `2018` multisociety advisory, the `2022` joint safety statement, and the `2024` ABCS mortality update. The folder now explicitly separates pre-`2018` intramuscular risk from post-guideline subcutaneous-only practice and does not repeat outdated blanket-mortality framing without date context.
- `PARTIALLY CONFIRMED` Cost framing is intentionally broad and low-confidence outside ASPS averages. Current-price evidence for `rib surgery`, `medical tourism`, and named-surgeon package pricing remained unstable and mostly marketing-page based, so those numbers were not elevated into quantitative claim files.
- `SEARCH GAP` Failed or weak-result search themes included: robust modern clinical evidence for `waist training` as a durable intervention; direct peer-reviewed outcome series for several named surgeons in the brief (`Daniel Bohl`, `Bohdan Pomahač`, `Deschamps-Braly`, `BeautyHub Dr. Lee`, `Konstantinos Gasparis`); and strong transfeminine studies reporting total pre/post `WHR` after combined `HRT + lipo + fat grafting +/- implants`.

## Electrolysis deep dive

- `CONFIRMED` Built a dedicated `research/hair-removal/electrolysis-deep/` chapter set and a companion `webapp/hair-removal-electrolysis.html` page so electrolysis is no longer compressed into a few cards inside the broader hair-removal portal. The new material separates galvanic chemistry, RF thermolysis, blend kinetics, multi-probe galvanic, machines, probes, insertion technique, parameters, evidence, trans workflows, home systems, licensing, and aftercare.
- `CONFIRMED` Regulatory device-class distinction was rechecked directly against FDA device records rather than repeating trade shorthand. Needle-type electrolysis epilators map to `21 CFR 878.5350` / product code `KCW`; tweezer-type epilators map to `21 CFR 878.5360` / `KCX`. This strengthens the home-systems and electric-tweezers chapter and keeps the "permanent removal" device family distinct from the historically challenged tweezer devices.
- `CONFIRMED` Load-bearing literature anchors in the new evidence chapter were verified directly: `Richards & Meharg 1995` PMID `7673501`; `Wagner et al. 1985` PMID `3989007`; `Olsen 1999` PMID `10025738`; `Kobayashi 1985` PMID `4044984`; `Salibian/Zhang 2022` PMC `9537259`.
- `CONFIRMED` Current machine-market claims were grounded in current manufacturer materials rather than older forum lore. Verified current sources include Dectro's Apilus line and xCell pages, Dectro's comparison chart, Instantronics' current site and Elite Spectrum purchase page, Clareblend's current site, and Silhouet-Tone's current electrolysis page.
- `CONFIRMED` Probe-family discussion now rests on currently retrievable product and technical sources instead of generic classroom shorthand. Used sources include Dectro's probe chart, Kobayashi's insulated-needle paper, current Sterex insulated-probe descriptions, and current Ballet / Laurier / probe-supply listings.
- `CORRECTED` The licensing chapter intentionally does **not** repeat stale figures from older trade lore. Current-source checking indicates Texas is better described as an unlicensed state for electrology in 2026 rather than a `150-hour` licensing state, and Oregon's current electrology training rule is `600 hours`, not `300`. California `600` and Massachusetts `1100` were directly confirmed from official state sources.
- `PARTIALLY CONFIRMED` Historical milestone detail around `Michel 1875` and `Bordier 1924` was verified to the level of consistent secondary historical sources and archival indexes, but I did not retrieve every original full primary text directly from a modern official archive. The sequencing and core claims are strong; some fine-grained historical detail remains secondary-source mediated.
- `PARTIALLY CONFIRMED` The current public documentation for `Apilus Cleo` is weak compared with xCell-era Dectro pages. The deep-dive treats Cleo as a real legacy / multi-probe lineage supported by accessory cross-reference and manufacturer-list evidence, but I did not locate a clean current official Dectro product page equivalent to the xCell documentation.
- `UNVERIFIED` I did not locate a single clean current official manufacturer page for every named Laurier probe variant requested in the brief. The probe chapter therefore uses a mixture of manufacturer, distributor, and current retailer documentation where necessary instead of pretending the primary-source set is cleaner than it is.

## 2026-04-18: Hair-removal pain reduction

- `CONFIRMED` Standard topical anesthetics have real but bounded value, and should not be conflated with the risk profile of compounded high-concentration topicals. Cross-check: direct laser-hair-removal RCTs for EMLA/ice and lidocaine-tetracaine peel align with AAD office-anesthesia guidance and current FDA warnings.
- `CONFIRMED` The fatal safety pattern is large-area application of potent topical anesthetic, often under occlusion, before laser hair removal. Cross-check: 2007 FDA advisory summaries, 2024 FDA warning, North Carolina Medical Board disciplinary record, and contemporaneous reporting on the Berg case all point the same way.
- `CONFIRMED` Long-pulse Nd:YAG is generally less comfortable than alexandrite or standard diode in comparative hair-removal trials, while lower-fluence repetitive diode protocols reduce pain at a probable efficacy-per-session cost. Cross-check: split-area laser comparison studies support this; wording in the summary was kept protocol-dependent rather than absolute.
- `PARTIALLY CONFIRMED` Nitrous oxide appears to be the cleanest office-based escalation between topicals and deeper sedation, but the literature directly in hair-removal clinics is thin. Cross-check: dermatologic-procedure cohort study and dermatology systematic review support the direction of effect, though not a hair-removal-specific deployment model.
- `PARTIALLY CONFIRMED` Menstrual-cycle timing likely matters for some patients, but the literature is heterogeneous and does not justify a rigid universal scheduling rule. Cross-check: review articles and phase-based experimental pain studies support cautious individualized wording only.
- `UNVERIFIED` Modern comparative pain data for `thermolysis` vs `galvanic` vs `blend` electrolysis remain weak. The modality-ranking language was therefore downgraded to expert/practice-level evidence instead of pretending there is a modern RCT base.
- `UNVERIFIED` I did not complete a structured FDA MAUDE extraction for pain-reduction-related hair-removal adverse events in this pass. This is logged as a human follow-up rather than silently implied as completed.

## Hair removal — pain reduction deepen pass

- `EXPANDED` Rewrote the seven main chapter files in `research/hair-removal-pain-reduction/` plus `_summary.md` into prose-first chapters with mechanism-level discussion rather than list shorthand. The deepen pass now explains topical delivery chemistry, nerve-block anatomy, nitrous physics, behavioral pain modulation, modality-specific pain mechanisms, population-specific operational problems, and the fatal-case retrospective.
- `CONFIRMED` `EMLA` PK framing against the FDA label: eutectic mixture chemistry, intact-skin onset being materially slower than liposomal lidocaine, and adult elimination half-life values for lidocaine and prilocaine. Sources checked 2026-04-18: FDA EMLA label, older EMLA pharmacology literature, and the comparative liposomal-lidocaine study (PMID `10594586`).
- `CONFIRMED` `Pliaglis` peel mechanics and PK claims against the FDA label and supporting clinical studies. Sources checked 2026-04-18: FDA Pliaglis label and randomized dermatology procedure studies (PMIDs `17760598`, `22830517`).
- `CONFIRMED` Methemoglobinaemia treatment language tightened to the standard regimen of methylene blue `1-2 mg/kg IV over about 5 minutes`, with explicit `G6PD` caution and exchange-transfusion fallback. Sources checked 2026-04-18: StatPearls, consensus reviews, and toxicology summaries.
- `CONFIRMED` `ASRA 2020` LAST rescue wording tightened: `20%` lipid emulsion `1.5 mL/kg` bolus, then `0.25 mL/kg/min`; maximum dose about `12 mL/kg`; smaller epinephrine dosing; avoid lidocaine-class antiarrhythmics. Sources checked 2026-04-18: ASRA 2020 checklist and RAPM update article.
- `CORRECTED` Fatal-case wording was narrowed to what is actually supportable in public records. The North Carolina Medical Board order remains the strongest source for `Shiri Berg` and `LaserGel Plus 10/10`. Publicly retrievable reporting supports the older Arizona fatality under `Blanca Bolanos`; I did not find a comparably clean primary public record for the alternate "Kubicek" naming, so that stronger wording was removed.
- `CORRECTED` Comparative laser-pain language is now more cautious and more honest. The deepen pass explicitly notes that at least one randomized alexandrite-vs-Nd:YAG leg trial in phototypes `III-IV` reported higher pain with alexandrite, which means the field does not support a universal "Nd:YAG always hurts more" claim.
- `CONFIRMED` Nitrous oxide office-use framing now includes `MAC ~104%`, negligible hepatic metabolism, diffusion-hypoxia rationale, methionine-synthase / `B12` inactivation, and scavenging requirements. Sources checked 2026-04-18: dermatology nitrous review (PMID `29701620`), dermatologic injection trial (PMID `31402695`), and AAOMS/ASDA model regulations.
- `EXPANDED` `webapp/hair-removal-pain.html` now mirrors the deeper research and adds a dedicated section on the physics of pain per modality plus a prose decision-tree section.
- `UNVERIFIED` I did not add new claim-file expansions under `research/hair-removal-pain-reduction/claims/` in this deepen pass. The main chapter files and page were rewritten first because they were the user-facing synthesis layers. A later pass could deepen each claim file individually if claim-level long-form expansion is required.

## Skin texture deepen pass

- `CONFIRMED` The revised framing now separates texture into topographical, optical, and tactile axes, and ties each axis back to specific tissue compartments rather than treating "texture" as one symptom bucket. Cross-check: skin anatomy and barrier reviews support the epidermis/DEJ/dermis/pilosebaceous-unit decomposition and the NMF/corneocyte contribution to roughness. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10373447/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC8583944/ ; https://pubmed.ncbi.nlm.nih.gov/33565637/
- `CONFIRMED` The aging-biology expansion was tightened around primary Fisher-pathway sources rather than generic anti-aging review language. The revised copy now anchors photoaging to UV -> MAPK/AP-1 -> MMP induction plus procollagen suppression, and to the later collagen-fragmentation positive-feedback loop. Sources: https://pubmed.ncbi.nlm.nih.gov/9502786/ ; https://pubmed.ncbi.nlm.nih.gov/10974019/ ; https://pubmed.ncbi.nlm.nih.gov/19116368/
- `CONFIRMED` Menopause / estrogen wording was expanded but kept conservative. The new summary uses Brincat's 1983-1987 skin-thickness/collagen studies for direction-of-effect and Thornton/Verdier-Sevrain for receptor-level interpretation, without pretending the older studies meet modern RCT standards. Sources: https://pubmed.ncbi.nlm.nih.gov/6416400/ ; https://pubmed.ncbi.nlm.nih.gov/3978054/ ; https://pubmed.ncbi.nlm.nih.gov/3828252/ ; https://pubmed.ncbi.nlm.nih.gov/16433679/ ; https://pubmed.ncbi.nlm.nih.gov/24194966/
- `PARTIALLY CONFIRMED` The pore literature remains weaker than internet summaries imply. I kept the strong claim that retinoids help visible pore prominence directionally, but avoided a precise "shrinkage" percentage because the often-cited Kang 2005 numbers are commonly laundered through secondary sources and broader photodamage studies rather than a clean pore-only RCT.
- `CONFIRMED` RF microneedling and fractional-laser sections were rewritten around device physics and hedged evidence tiers rather than brand marketing. The text now explicitly distinguishes insulated vs non-insulated needles, MTZ logic, and the stronger downtime/PIH burden of ablative fractional resurfacing. Sources: https://pubmed.ncbi.nlm.nih.gov/36826381/ ; https://www.sciencedirect.com/science/article/pii/S0738081X0700096X
- `CONFIRMED` Scar-treatment sequencing was tightened: rolling scars -> subcision, icepick scars -> TCA CROSS/punch logic, hypertrophic-keloid scars -> TAC/5-FU/PDL logic. This aligns the webapp and research files with the acne-scarring and scarring-general primers instead of letting the page imply one-device-fits-all resurfacing.
- `PARTIALLY CONFIRMED` Several device-specific claims requested in the brief remain only moderately evidenced in the public literature. The rewritten files intentionally avoid overclaiming around Morpheus8 adipose-remodeling precision, picosecond "non-thermal" rhetoric, and newer injectable skin boosters.

## Hair Removal — community layer critique 2026-04-18

- `CORRECTED` Named practitioner lists were tightened to current 2026-04 verification. `Electrology 3000`, `Aesthetics & Electrology Seattle`, and `Westrolysis` stayed in the active repeatedly-named list because they have current sites and/or booking pages. Sources: https://www.electrology3000.com/ ; https://www.aestheticsseattle.com/transcare ; https://www.fresha.com/a/aesthetics-electrology-seattle-seattle-509-olive-way-et7gbywu ; https://westrolysis.com/
- `CORRECTED` `Morgan Electrolysis`, `Vera Male`, `Rita Henn`, `Lupe's`, and `Ginger Chien` were removed from the active repeatedly-named list and moved to an older-references section because I could not locate a verified current 2026-04 site or booking URL for them. Older traces or the original brief were retained instead of presenting them as current fact. Sources: https://www.hairfacts.com/hair-removal-directory/united-states/washington/seattle-hair-removal/ ; [notes/hair-removal-community-brief.md](/workspace/darkarts.wiki/notes/hair-removal-community-brief.md)
- `CORRECTED` The insurance-code section was rewritten. `CPT 17380` remains valid for electrolysis epilation per 30 minutes. `CPT 15786/15787` were corrected as abrasion codes, not generic hair-removal codes. Sources: https://chk.static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_0266_coveragepositioncriteria_gender_reassignment_surgery.pdf ; https://www.va.gov/COMMUNITYCARE/docs/RO/Outpatient-DataTables/v3-27_Table-F.pdf
- `CORRECTED` `CPT 17110/17111` were downgraded from generic hair-removal framing to payer-specific usage only. Oregon OHA still uses them in its administrative laser authorization document, but they are benign-lesion destruction codes in standard CPT usage. Sources: https://www.oregon.gov/oha/OHP/Providers/Tools/Electrolysis-Requirements.pdf ; https://connect.stfm.org/practicemanagementhandbook/billingandcoding/outpatientprocedures
- `CORRECTED` The Medicaid matrix was narrowed to currently supportable claims. Washington Apple Health and MassHealth were kept as verified coverage examples; Oregon was kept as clearly surgery-prep-focused; California and New York were downgraded to partial / implementation-dependent because I did not locate clean statewide Medicaid facial-hair-removal language matching Massachusetts-level specificity. Sources: https://www.hca.wa.gov/billers-providers-partners/program-information-providers/transhealth-program ; https://www.hca.wa.gov/assets/103P-24-21-072.pdf ; https://www.mass.gov/info-details/gender-affirming-care-covered-by-masshealth ; https://www.mass.gov/guides/masshealth-guidelines-for-medical-necessity-determination-for-hair-removal ; https://www.oregon.gov/oha/OHP/Providers/Tools/Electrolysis-Requirements.pdf ; https://www.dhcs.ca.gov/formsandpubs/Documents/MMCDAPLsandPolicyLetters/APL2020/APL20-018.pdf ; https://www.dfs.ny.gov/system/files/documents/2025/07/Health-Insurance-for-Transgender-NewYorkers_0.pdf
- `CORRECTED` The WPATH reference was tightened to the actual medical-necessity hooks: Statement 2.1 plus Appendix E for medically necessary gender-affirming interventions, and Chapter 13 for pre-op genital hair removal. Older vague wording was replaced. Sources: https://www.tandfonline.com/doi/full/10.1080/26895269.2022.2100644 ; https://www.wpath.org/wp-content/uploads/2025/05/WPATH-Insurance-coding-and-EBM-Jaffe-and-Gorton-2023-Copy.pdf
- `CORRECTED` The community discussion of paradoxical hypertrichosis was aligned with the literature. The revised text now matches Moriguchi 2025 / Lanigan-line literature more closely: recognize early, stop treating expansion as a routine plateau, and if laser continues, switch to adequately dosed Nd:YAG or diode rather than simply repeating a weak alex/IPL protocol. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12040530/ ; https://pubmed.ncbi.nlm.nih.gov/20100274/ ; https://pubmed.ncbi.nlm.nih.gov/34057666/
- `CORRECTED` Community myths were made explicit and more honest: spironolactone alone will not erase a beard; laser will not clear blond or grey hairs; one full clearance is not the same as being done; cord block is regional, not universal; electrolysis is not pain-free. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9537259/ ; https://transcare.ucsf.edu/guidelines/hair-removal ; community sources cited in the revised files.
- `CORRECTED` Medical-tourism pricing was cut back to currently supportable examples. Thailand and Mexico remained because I found current live clinic or service pricing. Iran and Argentina were removed from settled claims because I could not get them to a strong enough 2026 verification standard in this pass. Sources: https://thailandaffirm.com/procedures/hair/laser-hair-removal ; https://www.yanhee.net/pricing-packages/plastic-surgery-prices/ ; https://doshasbeauty.com/en/depilacion-laser-cdmx-colonia-juarez/ ; https://www.blueskyclinic.com.mx/en/aesthetic-medicine-spa-mexico-city
- `CORRECTED` The companion HTML trans/community copy was updated to match the revised backend: narrower Medicaid wording, explicit SOC-8 citation logic, and the corrected community myths.
- `CORRECTED` The Army claim in the main summary was fixed. `Army Directive 2025-13` does exist and took effect July 7, 2025, but it is a grooming-policy change on shaving profiles and exceptions, not a hair-removal coverage directive. Source: https://home.army.mil/campbell/8917/5268/0853/IG_Update_25-3_-_Facial_Hair_Grooming_Standards-_July_25.pdf

## Hair removal — pain reduction critique 2026-04-18

- `CORRECTED` Fatal-case identity in the older Arizona case. Publicly retrievable reporting supports **Blanca Bolanos** (`6% lidocaine / 6% tetracaine`, both legs, seizures while driving, prolonged coma, died 2004), not a cleanly verifiable `Kristie Rae Kubicek` record. Corrected `research/hair-removal-pain-reduction/safety-and-fatal-cases.md` and `webapp/hair-removal-pain.html` accordingly.
- `CORRECTED` Berg case specifics. Tightened to what the accessible record supports: `LaserGel Plus 10/10` with `lidocaine 10%`, `tetracaine 10%`, `phenylephrine 0.5%`; NC Medical Board record documents distribution without proper prescribing oversight and `142 tubes` supplied; contemporaneous reporting supports large-area plastic-wrap use and seizure onset while driving. Removed invented dwell/BSA details.
- `CORRECTED` FDA advisory metadata. Updated to **February 6, 2007** and exact title **"Public Health Advisory: Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures."** Added archived FDA link rather than citing only summaries.
- `CORRECTED` Methaemoglobinaemia chemistry and treatment wording. Verified prilocaine metabolite as `o-toluidine`; added methylene blue dose `1-2 mg/kg IV over about 5 minutes`, repeat if needed; clarified that benzocaine is a more common offender than prilocaine in modern case series.
- `CORRECTED` Lidocaine ceilings. Rewrote the `4.5 mg/kg plain`, `7 mg/kg with epinephrine`, and `300 mg` ceiling language as **injected local anesthesia limits**, not topical-cream limits; noted that topical absorption depends on concentration, area, occlusion, skin integrity, and heat.
- `CORRECTED` ASRA lipid-rescue dosing. Updated to the **2020 ASRA LAST checklist** wording: `20% lipid emulsion`, `1.5 mL/kg bolus over 2-3 minutes`, then `0.25 mL/kg/min`, with repeat bolus/doubled infusion if still unstable and approximate total-dose ceiling `12 mL/kg`.
- `CORRECTED` EMLA infant claim. The current FDA label includes a restricted dosing table for `0 up to 3 months` on intact skin; it is **not** an absolute FDA non-approval for all infants under 3 months. Corrected the research and webapp to reflect the actual label plus exclusions for preterm neonates and infants under 12 months on methemoglobin-inducing drugs.
- `CORRECTED` Pliaglis adverse-reaction wording. Verified from the FDA label that the common figures are `erythema 47%`, `skin discoloration 16%`, and `edema 14%`; removed the more specific `dyspigmentation 16%` wording.
- `CORRECTED` Ice-versus-EMLA RCT phrasing. Verified the exact study as Roongpisuthipong et al., **J Am Acad Dermatol 2023**, PMID `36410628`. Replaced the earlier "noninferior" shorthand with the actual finding: no overall difference, with ice better immediately after treatment and cream better at 5 minutes.
- `CORRECTED` Menstrual-cycle pain phrasing. Downgraded the strong "luteal phase always worse" language to individualized, heterogeneous evidence only.
- `CORRECTED` Modality pain ranking confidence. Explicitly labeled laser ordering as roughly `C2` but electrolysis/mechanical ordering as mostly `C4`, and removed misleadingly precise numeric pain scores from the webapp.
- `CORRECTED` Nitrous availability language. Tightened the webapp and research files to say availability in dermatology/electrolysis is patchy and less established than in dentistry, labor and delivery, gynecology, and urology.
- `CORRECTED` Cannabis / kratom / gabapentin evidence level. Tightened to `C4` / weak direct procedural evidence rather than implying meaningful hair-removal-specific support.

## 2026-04-13: GLP-1 / anti-obesity medications

- `CONFIRMED` Tirzepatide has the largest average obesity-trial weight-loss effect among routine options. Cross-check: SURMOUNT-1 PubMed abstract and updated Endotext chapter both report `-15.0%`, `-19.5%`, and `-20.9%` at 72 weeks for 5/10/15 mg versus `-3.1%` placebo.
- `CONFIRMED` Semaglutide 2.4 mg is weaker than tirzepatide on average efficacy but still a major-effect medication. Cross-check: STEP 1 PubMed record reports `-14.9%` versus `-2.4%`; updated meta-analysis reports about `-11.80 percentage points` versus placebo.
- `CONFIRMED` Semaglutide has obesity-specific cardiovascular-outcomes evidence. Cross-check: FDA March 8, 2024 announcement and the SELECT PubMed record both support the `20%` MACE reduction claim in adults with overweight/obesity and established cardiovascular disease without diabetes.
- `CONFIRMED` Discontinuation commonly leads to regain. Cross-check: 2025 GLP-1RA discontinuation meta-analysis shows pooled regain after stopping, and STEP 4 plus SURMOUNT-4 withdrawal data show regain when active treatment is replaced with placebo.
- `CONFIRMED` GI adverse effects are the main class tolerability issue. Cross-check: STEP/Endotext semaglutide data and a 2025 GI safety meta-analysis both show materially higher GI event rates versus placebo.
- `CONFIRMED` Strong internet claims of an established suicidality signal are not supported by the current FDA position. Cross-check: FDA's January 10, 2026 drug safety communication explicitly says it found no increased risk and requested warning removal.
- `UNVERIFIED` Full-text evidence tables from the WHO obesity GLP-1 guideline were not extracted in this pass; the summary relies on the official WHO news release and should be upgraded later with the full guideline text if exact wording becomes important.

## 2026-04-13: Supplements for downcycle

- `PARTIALLY CONFIRMED` Psyllium and soluble fiber have a real helper effect, but it is small and heterogeneous. Cross-check: broader soluble-fiber meta-analyses support modest reductions in body weight and waist circumference, while narrower psyllium-specific reviews are somewhat more favorable than older viscous-fiber estimates.
- `CONFIRMED` Glucomannan has weaker support than psyllium and enough swallowing or obstruction baggage to justify a conservative ranking. Cross-check: an older systematic review and NIH/NCCIH consumer guidance both support a small or inconsistent efficacy signal plus mechanical-risk cautions.
- `PARTIALLY CONFIRMED` Protein supplements and meal replacements are better treated as diet-structure tools than as classic weight-loss supplements. Cross-check: meal-replacement and higher-protein meta-analyses support adherence and lean-mass preservation more strongly than any large independent scale-weight effect.
- `PARTIALLY CONFIRMED` Green tea extract and caffeine have a small real signal but not a high-impact one. Cross-check: a newer green-tea meta-analysis found statistically significant body-mass-related improvements, while Cochrane still supports describing the practical effect as small and not clinically important for most users.
- `PARTIALLY CONFIRMED` Berberine may produce modest weight or waist reductions, but it is overmarketed relative to effect size and trial quality. Cross-check: recent reviews show a small positive signal, while NIH and NCCIH style consumer guidance still supports a conservative anti-hype framing for the supplement category overall.
- `CONFIRMED` Chromium, garcinia cambogia, CLA, and generic fat-burner blends belong in the low-value hype bucket. Cross-check: NIH ODS and NCCIH both describe these categories as having small, inconsistent, or clinically unimpressive effects.

## 2026-04-14: Selective fat redistribution (first pass)

- `CONFIRMED` Liposuction is the strongest evidence-backed way in this draft to directly remove a local adipocyte depot, but it is a contouring procedure rather than a durable metabolic fix. Cross-check: liposuction systematic review on lipectomy/fat regain and the randomized visceral-fat compensation trial both support real local removal plus possible compensatory redistribution.
- `CONFIRMED` Cryolipolysis has real local body-contouring efficacy but weak whole-body weight effect. Cross-check: two recent cryolipolysis meta-analyses both support local circumference/fat-thickness reduction while not supporting a major scale-weight effect.
- `CONFIRMED` Paradoxical adipose hyperplasia is a real cryolipolysis risk and should be mentioned in any serious summary. Cross-check: original JAMA Dermatology case series and the 2025 PAH meta-analysis both support this.
- `CONFIRMED` Deoxycholic acid works for submental fat reduction, but that evidence should not be casually generalized to broad body-fat redistribution. Cross-check: FDA label plus phase III/systematic-review evidence all support submental efficacy and common local adverse effects.
- `PARTIALLY CONFIRMED` Topical aminophylline has a plausible local-girth signal, but the evidence base is small, old, and partly dependent on concurrent dieting. Cross-check: the 2023 systematic review is positive overall, while at least one placebo-controlled cellulite trial was negative.
- `PARTIALLY CONFIRMED` Topical caffeine can improve cellulite/circumference outcomes, but this is weaker than proving local adipocyte loss. Cross-check: older caffeine studies show positive cosmetic endpoints, but the endpoint quality is mostly cellulite/girth based.
- `UNVERIFIED` I did not find a peer-reviewed human efficacy publication for adipotide in this pass. Cross-check: a 2012 Arrowhead release confirms first-patient phase 1 dosing, but no later peer-reviewed human readout was located here.
- `CONFIRMED` Spot reduction via localized exercise does not hold up in controlled human studies. Cross-check: the 2011 abdominal-exercise trial and the 2013 one-leg resistance-training study both argue against meaningful adjacent-fat reduction.
- `PARTIALLY CONFIRMED` L-carnitine has a small nonspecific weight-loss signal in meta-analyses, but the April 13 ALCAR framing overstates its relevance to selective fat redistribution. Cross-check: multiple meta-analyses support at most a modest general effect and no meaningful local-targeting evidence.

## 2026-04-14: Selective fat redistribution (second pass)

- `CONFIRMED AND UPDATED` Paradoxical adipose hyperplasia incidence is around 0.22% per patient (95% CI 0.10-0.47) per the 2025 systematic review/meta-analysis (Aesthetic Surgery Journal Open Forum, 28 studies, ~13,000 patients). Cross-check: ASJOF 2025 pooled estimate plus BookStatPearls 2025 review. Internet and old marketing figures of 0.005% (1 in 20,000) are 40-100x lower than modern estimates. The draft must be updated to reflect this.
- `CONFIRMED` Modern cryolipolysis meta-analyses continue to show real local circumference and fat thickness reductions without meaningful whole-body weight effect. Cross-check: 2025 Obesity Reviews meta-analysis (PMID 40211915) and 2025 World Journal of Plastic Surgery meta-analysis (PMID 41607567).
- `CORRECTED` Adipotide is NOT an active experimental option. Cross-check: clinicaltrials.gov NCT01262664 shows trial TERMINATED with only 4 participants enrolled, actual completion 2 Jan 2019, no results posted, no peer-reviewed human readout exists. The "1 in 20,000" / "awaiting phase 1 readout" framing common in internet discussion is outdated.
- `CORRECTED` The Caruso 2007 aminophylline waist study had 50 total participants (25 per arm), not 25 as stated in the April 13 draft. More materially, it was not placebo-controlled; both arms were on 1200 kcal diet plus walking, participants/evaluators were unblinded, and no body composition was measured.
- `CONTRADICTED` The implicit framing that topical aminophylline is a "good effect size" intervention is contradicted by independent evidence. Cross-check: Collis 1999 (PMID 10654755) was a double-blind split-leg placebo-controlled RCT with ultrasound fat-depth endpoint and was fully null. The 2023 systematic review's positive tone rests heavily on Greenway/Bray split-leg trials; both authors hold patents on fat-spot-reducing creams filed 1985-1986 and publish without disclosure statements.
- `CONTRADICTED` The implicit framing that topical caffeine is a selective-fat-redistribution tool is contradicted by independent mechanism endpoints and independent placebo-controlled trials. Cross-check: Lupi 2007 microcirculation endpoints were null; Bielfeldt 2016 double-blind placebo-controlled right-left anti-cellulite cream trial was null; the positive literature is industry-linked.
- `PARTIALLY CONFIRMED` Spot reduction is disproven on meta-analysis, but the draft's "non-existent" language overshoots slightly. Cross-check: Ramirez-Campillo 2022 meta-analysis pooled effect -0.03 (null); Brobakken 2023 (n=16, 10 weeks, matched EE) positive trunk-fat signal; Scudiero/Paoli 2021 (n=14, no diet control) positive interleaved-circuit trunk effect. Neither positive trial overturns the meta-analysis but both deserve hedged mention.
- `CONFIRMED` HIFU for body contouring produces real adipocyte destruction histologically and meta-analytic circumference reduction, but sham-subtracted effect is ~1 cm in the pivotal Jewell 2011 RCT and HIFU was inferior to cryolipolysis in the one head-to-head RCT (Riyaz ASLMS 2018). Belongs in the comparator list at a "niche but plausible" tier.
- `CONFIRMED` Laser lipolysis splits cleanly into three tiers: laser-assisted liposuction (invasive variant, real; burns 1-6%), hyperthermic 1060 nm SculpSure (niche peer of cryolipolysis), and low-level laser therapy / Zerona / Erchonia (hype, industry-dominated, contradicted by independent mechanism study). All three should be discussed separately, not pooled.
- `CONFIRMED` HIFEM / Emsculpt is primarily a muscle-hypertrophy device. Cross-check: only one sham-controlled RCT (Samuels 2022, industry-authored, ultrasound-only), 86-100% industry-affiliated authorship across reviews (Kinney 2023, Annals of Plastic Surgery 2025), reported fat thickness reductions (~5-8 mm) near ultrasound measurement error (~2 mm SEM). Any real fat signal in Emsculpt NEO likely comes from the RF thermal component, not HIFEM itself.
- `CONFIRMED` Off-label body-area deoxycholic acid has only low-level evidence (case series and small cohorts) despite mechanism plausibility. Cross-check: Shamban 2019 JDD systematic review; ASPS 2019 position statement explicitly non-recommending for routine non-submental use; small 2024-2025 flank and arm trials.
- `CONFIRMED` The FDA issued a January 2024 consumer safety communication against Aqualyx, Lipodissolve, Lipo Lab, Kabelline, and similar unapproved "fat-dissolving" injections, citing permanent scarring, skin deformation, and painful subcutaneous nodules. Brazil's ANVISA banned PPC in 2002. Mycobacterial abscesses are a documented complication.
- `CONFIRMED` CBL-514 (Caliway Biopharmaceuticals) is the most credible near-term emerging injectable lipolytic candidate with 2025 Phase 2b positive abdominal-fat RCT data. Phase 3 ongoing; not yet approved.
- `UNVERIFIED` The specific claim that adipotide's phase 1 trial was terminated "due to human nephrotoxicity" is consistent with the documented preclinical renal signal but is not confirmed by any primary MD Anderson or Arrowhead statement. Published facts support termination; the specific mechanism is plausible but not officially declared.

## 2026-04-14: Selective fat redistribution (third pass, independent verification)

This pass was run to validate the earlier ChatGPT-authored research after the user expressed doubt. Spawned three parallel agents: aminophylline deep-verify, adipotide proponents, and claims audit across c001-c005/c008-c018.

- `CONFIRMED AND EXTENDED` The user's recollection that topical aminophylline helps in the presence of concurrent weight loss but not on its own is supported by the primary literature. Cross-check: Greenway/Bray 1995 Trials 5 and 6 (no-diet sub-trials) produced null/minimal effect versus 0.77-3.08 cm thigh differentials in the deficit sub-trials; Caruso 2007 had both arms on 1200 kcal plus walking; Collis 1999 (the one double-blind placebo-controlled ultrasound-endpoint RCT) instructed lifestyle maintenance and was fully null. Important confound: deficit-dependence and better blinding cannot be separated in this dataset because Collis is BOTH the only properly-blinded trial AND the only no-deficit trial. Added to c007.
- `CONFIRMED` Topical aminophylline is NOT an alpha-2 adrenergic antagonist; it is a non-selective PDE inhibitor and adenosine-receptor antagonist. Depot selectivity arises because female gluteofemoral subcutaneous fat is alpha-2-rich (Gi-mediated cAMP suppression) and PDE inhibition bypasses that brake downstream. The April 13 draft's "inhibits dual PDE which causes cAMP surge" is directionally right but misses the depot-selectivity mechanism. Added clarification to c007.
- `CONFIRMED` Adipotide continues to be sold to consumers as a "research peptide" by at least ten active vendors as of 2026 (Peptide Sciences, Core Peptides, BehemothLabz, Biotech Peptides, Infinity Peptide, LeoLab RX, Pure Health Peptides, 22exo, Peptides Alpha, Raw Amino). Dominant forum dose protocol is the primate-scaled ~0.43 mg/kg/day SC × 28 days. Despite a decade of availability, the forum record contains essentially no convincing self-reported efficacy logs.
- `CONFIRMED` The single loudest real-world adipotide safety signal is Bostin Loyd, a bodybuilder who publicly attributed his stage-5 chronic kidney failure to adipotide self-use at ~5 mg/day (roughly 5x typical forum doses) before his 2022 death from aortic dissection with documented end-stage renal disease. The polypharmacy confound (AAS, insulin, SARMs, diuretics) is real; causation is not established, but it is the loudest publicly named case of a self-experimenter reaching dialysis after adipotide. Cross-check: Fitness Volt and Muscle Insider coverage. Added to c006.
- `CONFIRMED` No adipotide veterinary program exists despite 2012-era press speculation; no reformulation or successor peptide has reached Phase 1 as of 2026; Arap/Pasqualini lab publications since 2011 are basic-science mechanism work (e.g., CD36/prohibitin 2021) rather than drug-reformulation attempts.
- `CORRECTED` The PAH "40-100x higher than 1 in 20,000" framing is imprecise. Correct arithmetic: ~44x at the meta-analytic point estimate (0.22%), up to ~92x at the confidence interval upper bound (0.47%). Fixed in c004, c018, and the summary.
- `ADDED CONTEXT` The Samuels 2022 Emsculpt NEO sham-RCT lost 44 of 72 subjects to 6-month follow-up, but this attrition was attributed to COVID-19 rather than intervention-related dropout. Clarified in c016.
- `TIGHTENED` Hernandez 2011 liposuction reaccumulation location: "upper abdomen" is supported by the primary paper; "shoulders and triceps" appears in press coverage rather than in the quoted results text. c003 updated to reflect this distinction.
- `CONFIRMED NO FABRICATIONS` The audit pass cross-checked PMIDs and URLs in c001-c005 and c008-c018 (not re-auditing c006/c007 which had dedicated deep-verify). No fabricated citations, no entity swaps (DCA/PPC, Liposonix/UltraShape, laser sub-types all distinguished correctly), no wrong PMIDs.
- `ADDED` Yohimbine and other alpha-2 antagonists: mechanism-interesting for depot selectivity but human-evidence-weak (Kucio 1991 null, no imaging-endpoint RCT showing preferential stubborn-fat loss). Added to c013 as a skeptical one-liner.
- `ADDED` AOD9604 (abandoned Phase 2B failure), 5-amino-1MQ (preclinical NNMT inhibitor), and topical capsaicin/synephrine/forskolin as skeptical one-liners in c013.
- `CROSS-REFERENCED` Retatrutide Phase 2 body-composition substudy shows preferential VAT reduction (24.5-39.1% VAT vs 13.2-43.5% ASAT at 48 weeks); this is arguably the cleanest current "selective fat redistribution" signal in medicine but lives in the incretin/medication track. Flagged in the summary for possible cross-reference from the writeup.

## Cross-check: weight-gain-methods first-wave claim files (2026-04-14)

## Breast development / chest surgery pass (2026-05-06)

- `CONFIRMED` `research/breast-development/_summary.md` and companion files were built around the strongest objective adult transfeminine cohort data rather than forum lore. The central ranking anchor is de Blok `2018` plus de Blok `2021`: modest first-year growth, continued volume increase through `3 years`, mean final volume around `100 cc`, and frequent `<A cup` outcomes despite ongoing development.
- `CONFIRMED` The common online claim that "higher estradiol means better breast growth" did not survive cross-checking. de Blok `2018`, Tebbens `2022`, Nolan/Cheung `2021`, and the `2025` estradiol-concentration systematic review all point away from a clean dose-response threshold or route superiority for breast outcomes once treatment is otherwise adequate.
- `CONFIRMED` The antiandrogen recommendation was updated to reflect the `2025` randomized clinical trial comparing `spironolactone 100 mg/day` with `cyproterone acetate 12.5 mg/day`. The rewrite now states clearly that cyproterone suppressed testosterone more strongly but did **not** outperform spironolactone on breast-growth endpoints over `6 months`.
- `PARTIALLY CONFIRMED` Progesterone remains intentionally framed as unresolved rather than dismissed or embraced. Cross-check found the `2022` systematic review and older guideline language supporting "no conclusive evidence" through 2024, plus an Amsterdam UMC report dated `September 5, 2025` describing a `90`-participant randomized trial with up to `30%` greater volume gain. Because I did not verify a full peer-reviewed efficacy paper for that positive result, progesterone was kept at `C2` / uncertainty-tier rather than promoted to standard practice.
- `CONFIRMED` Breast-cancer surveillance language was cross-checked against both the Dutch nationwide cohort and current ACR-facing screening guidance. The folder now states the `15/2260`, `median 18 years`, `SIR 46.7 vs cis men`, `0.3 vs cis women` figures and the ACR average-risk screening threshold of age `40` with `>=5 years` of hormone use.
- `CONFIRMED` Transfeminine augmentation recommendations were kept anatomy-first. Cross-checking the augmentation review/meta-analysis literature supported the narrower claim that infection / capsular-contracture rates are broadly similar to cis augmentation literature while malposition and hematoma/seroma are somewhat more frequent, with chest width / lateralized NAC position driving larger implant selection.
- `CONFIRMED` Transmasculine top-surgery technique ranking was tightened around revision and complication data rather than surgeon marketing. The Dutch `2024` cohort and the `2018` systematic review support a real tradeoff: lower-scar approaches are not automatically lower-burden overall and may carry higher revision or reoperation rates in selected subgroups.
- `LIMITATION` I did not verify a strong dedicated surgeon-volume study that quantifies a clean case-number threshold for better top-surgery outcomes. The folder therefore says surgeon experience likely matters but stops short of giving a numeric rule.
- `LIMITATION` Sensation-preservation evidence for `buttonhole`, `inferior pedicle`, and related nipple-preserving variants remains materially weaker than the complication / revision literature. The folder states this explicitly and keeps sensation-preservation claims below `C1`.
- `SEARCH GAP` Failed or weak-result search themes included: exact peer-reviewed publication of the positive `2025` Amsterdam progesterone efficacy results; a modern controlled study of `dutasteride` or `finasteride` for stalled transfeminine breast growth; and a robust comparative series quantifying erotic nipple sensation preservation across `buttonhole` versus `periareolar` versus `DI-FNG`.

## Shoulders pass (2026-05-06)

- `CONFIRMED` Built `research/shoulders/` around seven quantitative claim files rather than a vibes-only anatomy page. The strongest anchors are the `2025` CT skeletal-dimensions paper showing adult-start GAHT does not shrink shoulder width, the `2018-2021` GAHT body-composition studies showing real but modest upper-body lean-mass loss, and the clavicle biomechanics literature showing `>=10%` shortening alters scapular kinematics.
- `CONFIRMED` The summary now explicitly distinguishes `bone width`, `soft-tissue width`, and `relative-ratio width`. This corrected the most common reasoning failure in shoulder discourse, where clavicle length, deltoid bulk, trap prominence, and waist/hip context are treated as one thing.
- `CONFIRMED` Adult skeletal-width claims were cross-checked directly against `PMC12012668`. The folder now states the exact `2.8 cm` untreated AMAB-vs-AFAB shoulder-width difference and the key negative result: adult GAHT without early puberty suppression did not produce smaller shoulders.
- `CONFIRMED` HRT-related upper-body muscle-loss claims were cross-checked against multiple independent sources: Klaver `2018`, Yun `2021`, Scharff `2019`, and the larger systematic review on body composition. The writeup now stays honest that these are muscle and strength changes, not direct shoulder-span measurements.
- `CONFIRMED` The clavicle-shortening caution was tightened around actual biomechanics rather than community lore. Combining the clavicle-length morphometry paper with Matsumura `2010` makes it clear that the commonly marketed `1.5-3.0 cm` per-side resections generally fall into the `>=10%` shortening zone where scapular kinematics change in cadaveric models.
- `PARTIALLY CONFIRMED` Current surgeon-market verification is uneven. `Yonsei Baro Chuk Hospital` and `WIH International Hospital` were verified as current official clavicle-reduction offerings, but the brief’s named entities `BeautyHub / Geon Kang`, `Charlie Chen Taiwan`, `Daniel Bohl Chicago`, `Konstantinos Gasparis Greece`, and `Bohdan Pomahač` did not cleanly verify as current clavicle-shortening providers from primary official sources.
- `LIMITATION` I did not locate a strong peer-reviewed aesthetic case series for elective bilateral cosmetic clavicle shortening with denominator-level complication rates, standardized pre/post width measurements, and long-term follow-up. The surgery section therefore relies on a mix of current official offering pages and indirect orthopedic literature, and says so explicitly.
- `SEARCH GAP` Failed or weak-result search themes included: `published bilateral cosmetic clavicle shortening case series`, `Daniel Bohl clavicle reduction`, `Charlie Chen Taiwan clavicle shortening`, `Geon Kang clavicle reduction`, `Konstantinos Gasparis clavicle shortening`, and `adult transfeminine shoulder-span change in centimeters after GAHT`.

Independent audit of c001–c015 in `research/weight-gain-methods/claims/`, plus consistency check against `_summary.md`. Reviewer was not one of the original authoring agents. Methodology: for each file, picked 2–3 load-bearing claims and independently re-searched to find a second authoritative source; cross-checked every cited URL for plausibility (PubMed PMIDs / JAMA/NEJM/ASCO DOIs / FDA labels). No claim files were edited.

### Summary
- Files audited: 15 (c001–c015)
- Load-bearing claims checked: 32
- CONFIRMED: 26
- CORRECTED: 2
- PARTIALLY CONFIRMED: 3
- UNVERIFIED: 1
- CONTRADICTED: 0

Overall quality is HIGH. The first-wave claim files are notably tighter than the selective-fat-redistribution first-wave was: no fabricated PMIDs detected in the sample, effect sizes match independent retrieval, and the deflationary framing (MK-677 mostly water; anamorelin no handgrip; tesamorelin reduces visceral fat not bulks; nuts don't cause proportional weight gain; topical local-adipogenesis agents have no independent RCT) is correctly aligned with the peer-reviewed evidence. The MK-677 Svensson/Murphy disambiguation flagged earlier was handled correctly in c006.

### Per-claim findings

**c001 — diet structure, surplus, rate**

- *Bhasin-not-relevant here; primary load-bearing claims are the 10–20% surplus + 0.25–0.5%/wk rate and the Ribeiro 2023 trial.* Ribeiro 2023 (PMC10620361): **CONFIRMED**. Independent retrieval: Sports Medicine Open 2023 (Ribeiro et al., 8 weeks, 5% vs 15% surplus in resistance-trained men) reported no additional hypertrophy for the larger surplus but more fat accumulation — matches claim. Source: https://link.springer.com/article/10.1186/s40798-023-00651-y
- Bouchard 1990 twin overfeeding (NEJM): **CONFIRMED**. 12 monozygotic pairs, +1000 kcal/day × 84 days, mean gain 8.1 kg (range 4.3–13.3). Matches claim. Source: https://www.nejm.org/doi/full/10.1056/NEJM199005243222101
- Levine 1999 NEAT overfeeding: **CONFIRMED**. 16 subjects, 1000 kcal/d × 8 weeks; NEAT change range -98 to +692 kcal/d, ~10-fold variation in fat gain. Matches claim.

**c002 — calorie-dense foods and insulin**

- Nuts meta-analyses neutral on weight: **CONFIRMED**. Multiple independent meta-analyses align: Nishi 2021 Obesity Reviews (PMID 34494363), Guarneiri 2020 Advances in Nutrition (PMID 32945861) — "Intake of Nuts or Nut Products Does Not Lead to Weight Gain". Mohammadi-Sartang 2017 (PMID 28160450) also found no BMI effect. The framing "whole nuts are weaker bulking-per-calorie than their label" is correctly supported.
- Insulin activates adipocyte LPL / suppresses HSL: **CONFIRMED**. Textbook-level; Kersten 2014 review (AJP Endocrinol Metab) supports.
- The "carb+fat insulin-stacking" heuristic labeled as C4: **CONFIRMED** (correctly hedged). Isocaloric feeding trials (Hall 2016 Ludwig carb-insulin test, NuSI-funded) consistently fail to show a fat-gain advantage for high-carb over high-fat at matched kcal — claim file's skeptical framing is evidence-correct.

**c003 — resistance training for lean mass**

- Schoenfeld 2017 volume meta-analysis, ~10–20 hard sets/muscle/week dose-response: **CONFIRMED**. PMID 27433992 retrieves; graded dose-response with ~0.37%/set reported. 2022 Baz-Valle systematic review corroborates.
- Schoenfeld 2016 frequency meta-analysis (2x/week > 1x/week volume-equated): **CONFIRMED**. PMID 27102172.
- Aragon/McDonald heuristic muscle-gain rates correctly tagged **C4** (coach wisdom, not RCT). Appropriate confidence labeling.

**c004 — cyproheptadine / mirtazapine**

- Homnick 2004 cystic fibrosis cyproheptadine RCT: **CONFIRMED** (PMID 15211696 exists, matches 12-week CF population description).
- Hunter 2021 mirtazapine cachexia negative RCT: **CONFIRMED**. Independent retrieval: JPSM 2021 (PMID 34051293) double-blind placebo-controlled 8-week mirtazapine 15 mg — "did not improve appetite, body weight, hand-grip strength or quality of life." The claim file says "28 days" but the published primary endpoint in the trial is actually day 28 measurement within an 8-week treatment protocol — **PARTIALLY CONFIRMED, minor wording tightening needed** (day-28 endpoint within an 8-week trial; the "× 28 days" phrasing is slightly inaccurate). Not a ranking-changing error.
- Najib 2014 cyproheptadine pediatric undernutrition: **CONFIRMED**. BMI delta of 0.83 vs 0.15 kg/m² matches the published data (PMC4442838).

**c005 — megestrol / dronabinol / olanzapine**

- Sandhya 2023 JCO olanzapine 60% vs 9% ≥5% weight gain: **CONFIRMED**. Independent retrieval (PMID 36977285, JCO 41(14):2617–2627): at 12 weeks, 35/58 (60%) olanzapine vs 5/54 (9%) placebo (p<0.001). Exact numbers match claim.
- Jatoi 2002 NCCTG megestrol vs dronabinol: **CONFIRMED**. Megestrol 75% vs dronabinol 49% appetite improvement, 11% vs 3% ≥10% weight gain — matches claim (PMID 11786587).
- Attia 2019 olanzapine in AN: **CONFIRMED on effect size** but **PARTIALLY CONFIRMED on absolute weight**. Independent retrieval (PMID 30654643): BMI rate of change 0.259 vs 0.095 BMI/month; the "approximately 6.7 kg vs 4.2 kg" weight figures in the claim file are not directly stated in the primary abstract — the trial reports the BMI-rate delta as the primary finding. The 6.7 / 4.2 absolute kg figures may be derived or from a secondary source. Recommend: rephrase to "BMI rate of change 0.259 vs 0.095 per month" and drop the specific kg figures unless a secondary source is added. Not ranking-changing but tightens precision.
- Bodenner 2007 megestrol nursing-home mortality: **CONFIRMED**. Independent retrieval (PMID 17719516): n=709 MA-treated vs 1418 matched controls; median survival 23.9 vs 31.2 months (p<0.001), no significant weight benefit. Matches claim.

**c006 — MK-677 / anamorelin / relamorelin**

- Nass 2008 MK-677 FFM +1.1 kg and +2.7 kg body weight: **CONFIRMED**. Independent retrieval (PMID 18981485, Annals of Internal Medicine): FFM 1.1 kg (0.7–1.5) vs −0.5 kg placebo; body-weight increase 2.7 kg vs 0.8 kg. Limb fat +1.1 kg vs +0.24 kg placebo. All numbers match exactly. Excellent accuracy.
- **Svensson 1998 vs Murphy 2001 disambiguation: CONFIRMED HANDLED CORRECTLY.** Independent retrieval: Svensson 1998 (PMID 9467542, JCEM 83(2):362–369) = 24 obese males × 2 months MK-677 body-composition study; Murphy 2001 (PMID 11238495, JCEM 86(3):1116, n=292 postmenopausal osteoporotic women × 18 months, combined with alendronate, bone-marker primary endpoint). The flagged-risk conflation from an earlier brief has been correctly resolved. The c006 framing explicitly calls out the prior confusion.
- Adunsky hip-fracture CHF 6.5% vs 1.7%: **CONFIRMED**. Independent retrieval (PMID 21067829): 4/62 (6.5%) MK-677 vs 1/61 (1.7%) placebo developed CHF; trial terminated early. Matches claim. (The claim file cross-verification flag "no" is conservative — can now be marked "yes" in a future pass.)
- ROMANA 1 / ROMANA 2 anamorelin +0.99 / +0.65 kg LBM without handgrip improvement: **CONFIRMED**. Lancet Oncology 2016 (PMID 26906526) numbers match exactly.

**c007 — tesamorelin / CJC-1295 / ipamorelin / sermorelin**

- Tesamorelin LBM +1.42 kg meta-analysis: **CONFIRMED**. Independent retrieval (PMID 41545261, Obesity Medicine 2026 meta-analysis): LBM +1.42 kg (95% CI 1.13–1.71), VAT −27.71 cm², hepatic fat −4.28%, trunk fat −1.18 kg, limb fat −0.22 kg. Numbers match exactly.
- Tesamorelin FDA approval for HIV lipodystrophy visceral-fat reduction (not bulking): **CONFIRMED**. FDA label (2019 revision) and NEJM Falutz 2007 (PMID NEJMoa072375) confirm indication.
- Teichman 2006 CJC-1295 phase 1 PK: **CONFIRMED** (PMID 16352683; JCEM 91(3):799).
- Sermorelin discontinuation "not for safety" FDA determination: **CONFIRMED**. Federal Register 2013 (2013-04827) withdrawal determination verifies claim.

**c008 — AAS and SARMs**

- **Bhasin 1996 6.1 kg FFM over 10 weeks at 600 mg/wk testosterone enanthate + training: CONFIRMED.** Independent retrieval (NEJM 335:1, PMID 8637535): testosterone+exercise group gained ~6.1 kg FFM in 10 weeks; placebo+exercise ~1.9 kg; testosterone-alone ~3.2 kg. All numbers match the claim exactly. Prior flagged-risk area cleared.
- Bhasin 2001 dose-response 25/50/125/300/600 mg × 20 weeks: **CONFIRMED** (PMID 11701431, AJP Endocrinol Metab).
- 2025 AAS meta-analysis LVEF difference −2.25% (95% CI −3.41 to −1.09): **CONFIRMED** per IJC 2025 meta-analysis URL (S0167527325009398) — 35 studies, ~2000 men; numbers plausible and cross-referenced via PMC12467473.
- Dalton ostarine phase 2 +1.4 kg LBM at 3 mg/day × 12 weeks: **CONFIRMED** (ASCO 2007 abstract + Dalton 2011 J Cachexia Sarcopenia Muscle, PMC4111291).
- 20.5% persistent HPG-axis non-recovery (Rasmussen 2021 cohort): **CONFIRMED** (PMID 33351319) — 79.5% recovery / 20.5% non-recovery consistent with reported cohort data.
- GTx enobosarm POWER phase 3 failed co-primary functional endpoint: **CONFIRMED**. Clinically well-documented via Crawford 2016 (Current Oncology Reports) and Dobs 2013. Matches claim.

**c009 — GH / IGF-1 / myostatin inhibitors**

- **Liu 2007 Annals systematic review GH in healthy elderly, ~2 kg LBM shift: CONFIRMED.** Independent retrieval (PMID 17227934; Annals of Internal Medicine 146:104, 31 articles, 18 study populations, 220 participants): pooled LBM increase 2.1 kg (95% CI 1.3–2.9); fat mass decrease 2.1 kg; no strength/function benefit; increased rates of edema, arthralgia, carpal tunnel, gynecomastia, diabetes. Matches claim exactly.

## Hair removal — community deepen pass

- `EXPANDED` `research/hair-removal/community-trans.md` was rebuilt from a short link-and-warning layer into a long-form chapter answering the question, "What does the trans community know about hair removal that the clinical literature tends to flatten or omit?" The rewrite now covers the historical accumulation of knowledge across Susan's Place, Hairtell, Andrea James's broader directory ecosystem, and Reddit; a stage-by-stage transfeminine treatment timeline from discovery through maintenance; currently verifiable clinic profiles; surgeon-queue logistics; medical-tourism economics; and the emotional / dissociation burden. Sources added in this pass include UCSF Transgender Care hair-removal guidance, Salibian/Zhang 2022 pre-vaginoplasty comparison (PMC9537259), Crane Center hair-removal recommendations and template, Marci Bowers's genital-hair-removal page, Kamol Hospital's SRS hair-removal instructions, live clinic pages for Electrology 3000, Aesthetics & Electrology Seattle, Westrolysis, Goddess Electrolysis, eleQTro spot, PNW Electrology, Eden Electrolysis, and Allura, plus archived/current community threads from Hairtell, Susan's Place, `r/MtF`, `r/asktransgender`, `r/DrWillPowers`, `r/TransLater`, and related Reddit communities retrieved 2026-04-18.
- `EXPANDED` `research/hair-removal/community-practitioner-selection.md` was rewritten to answer, "How should a patient in 2026 actually evaluate a laser clinic or electrology practice beyond generic credentials?" The new chapter now treats franchises, dermatology-owned practices, and solo electrologists as different business models with different failure modes; it explains why chain pricing and contract structures matter; it turns the consult checklist into a prose screening script; it decodes device inventory as a practical proxy for Fitzpatrick-range competence; and it grounds operator-scope discussion in real state-board rules rather than folklore. Sources added include Ideal Image's current laser page and SEV transition FAQ, LaserAway terms and device-language pages, Milan's company/about materials, Skin Laundry and Sono Bello public service pages as contrast examples, the California Medical Board's med-spa / medical-assistant guidance, Massachusetts electrology and IPL board materials, Florida electrology board and rule references, the American Electrology Association's state-license map, and manufacturer pages for Candela GentleMax platforms, Cynosure Elite iQ, Lumenis LightSheer, Alma Soprano, and Sciton BARE/BAREit.
- `EXPANDED` `research/hair-removal/community-sessions.md` was rewritten around the question, "What does a competent patient-operating playbook look like before, during, and after sessions, and which folk rules survive evidence-checking?" The result is now a prose guide to pre-session preparation, shaving timing, waxing/tweezing avoidance, cadence planning by body site, combining laser reduction with electrolysis cleanup, expected shedding patterns, photo documentation, pain-control escalation, and early recognition of paradoxical hypertrichosis. Sources added include the ASDS 2017 isotretinoin consensus statement (PMID 28498204), current clinic prep guidance from Ideal Image and Allura, paradoxical-hypertrichosis reviews including Lanigan and more recent review literature, and supporting community threads documenting how patients recognize shedding vs regrowth and when they decide a laser course is failing.
- `EXPANDED` `research/hair-removal/community-cost-insurance.md` was rebuilt to answer, "What does hair removal actually cost in practice, and how do patients get gender-affirming coverage approved now?" The rewrite now walks through hour-based and package-based cost logic, current verified metro pricing, surgery-prep economics, the limits of copying billing codes between payers, the structure of a successful prior-authorization packet, Medicaid reality in 2025-26, employer-plan variation, the current Section 1557 litigation environment, and the narrower circumstances where medical-tourism ROI still works. Sources added include live pricing pages for Westrolysis, Aesthetics & Electrology Seattle, Electrology 3000, and Goddess Electrolysis; Salibian/Zhang 2022; Washington Apple Health transhealth materials; MassHealth's 2025 hair-removal guideline and coverage pages; Aetna CPB 0615; UnitedHealthcare's 2026 gender-dysphoria treatment policy; the Movement Advancement Project Medicaid tracker; HHS's current Section 1557 litigation/status page; and Amazon's employer-specific Aetna transgender benefits guide.
- `EXPANDED` `research/hair-removal/community-pitfalls.md` was rewritten to answer, "What predictable failure patterns actually damage outcomes, and what does recovery or escalation look like?" The new chapter converts each major pitfall from a one-line warning into mechanism plus recognition plus recovery plus escalation: package-contract traps, burn/PIH patterns, tech turnover, tanned-skin injuries, paradoxical hypertrichosis misread as under-treatment, electrolysis scarring and overtreatment, Fitz V-VI pigment complications, incomplete vaginoplasty prep, tweezing during active laser courses, and permanence overpromising. Sources added include Jalian et al. 2014 on laser-surgery lawsuits (PMID 24048466), updated paradoxical-hypertrichosis reviews, current clinic contract language where publicly posted, state-board / regulatory materials for complaint pathways, FDA / HHS public safety materials already used elsewhere in the hair-removal set, and community case discussions illustrating how these problems are recognized in real time.
- `REWRITTEN` The `## Community-knowledge layer` section in `research/hair-removal/_summary.md` now answers a different question from the companion files: "How should a reader navigate the community layer without duplicating it?" Instead of restating the whole argument, it now summarizes the role of each community chapter and links the reader to the correct file for trans logistics, practitioner selection, session operations, cost/coverage reality, and failure modes. This was an architecture correction rather than a new evidence chapter.
- `UPDATED` `webapp/hair-removal.html` was revised in the affected community-facing sections so the page now reflects the deeper research pass instead of underselling it. The trans section now explicitly says the community layer changes logistics and decision-making even when the underlying physics stay the same, and the cost section now frames coverage as an administrative and network problem rather than a purely scientific one. The card language was upgraded from brief "mentions" to actual discussions, with references aligned to the rewritten community research chapters.
- `LIMITATION` This pass did not produce a literal 50-state appendix for laser-operator scope or a fully verified surgeon-authored hair-removal requirement page for every surgeon named in the original brief. Where public, current, primary-source verification was weak or ambiguous, the rewritten files now say so directly rather than laundering community memory into false certainty.
- GH in healthy young athletes — FFM gain fully explained by extracellular water: **CONFIRMED** (Meinhardt 2010 Annals PMID 20439575). 
- Mecasermin (Increlex) pediatric approval + 42% hypoglycemia: **CONFIRMED** (FDA label).
- Myostatin inhibitor failures (ACE-031, domagrozumab): **CONFIRMED** — Campbell 2017, Pfizer domagrozumab failure well-documented.

**c010 — topical local adipogenesis**

- **Volufiline Sederma claim, ~6.5% breast volume at 2% product: PARTIALLY CONFIRMED.** Independent retrieval of Sederma marketing materials and third-party reviews (e.g., Dr. Rachel Ho 2024 review) finds the Sederma-reported breast-volume increase more commonly cited as ~2.2% at 5% Volufiline applied twice daily × 56 days. The exact "~6.5% at 2%" figure appears in one Sederma brochure version; the "~2.2% at 5%" figure appears in more-cited secondary writeups. Both trace back to Sederma's own data so the C2 confidence tier is appropriate, but the number is brand/condition-dependent and the claim should add "(manufacturer-reported; different Sederma materials cite different percentages at different product concentrations)" for precision.
- No independent peer-reviewed RCT for Adifyline / volufiline / topical pioglitazone in local-adipogenesis indication: **CONFIRMED**. Searches for "acetyl hexapeptide-38", "volufiline", "sarsasapogenin adipogenesis", "topical pioglitazone adipose" on PubMed return no independent human imaging-endpoint RCT as of this audit. The absence-of-evidence finding holds.
- Oral pioglitazone ~2–4 kg weight gain at standard doses: **CONFIRMED** (Nissen 2007 meta-analysis PMID 17327501; PROactive trial PMID 16505479 reports mean weight gain of ~3.6 kg pioglitazone vs ~0.4 kg placebo at end of study).
- The 0.2% transdermal penetration figure correctly tagged **C4** (forum source). Accurate framing.

**c011 — clinical cachexia context**

- **Fearon 2011 consensus definition (weight loss >5% over 6 mo, or >2% with BMI <20 or sarcopenia): CONFIRMED.** Independent retrieval (PMID 21296615, Lancet Oncology 12:489): exact wording matches — "weight loss >5%, or weight loss >2% in individuals already showing depletion according to current bodyweight and height (BMI <20 kg/m²) or skeletal muscle mass (sarcopenia)". Pre-cachexia / cachexia / refractory-cachexia staging correctly described.
- ASCO 2020 cachexia guideline (Roeland et al.): **CONFIRMED** (JCO 38:2438, DOI 10.1200/JCO.20.00611) — "may offer" progestins or corticosteroids; does NOT recommend cannabinoids, olanzapine (as of 2020), or anamorelin. Matches claim.
- ASCO 2023 rapid update elevating low-dose olanzapine: **CONFIRMED** (JCO 41:4178, DOI 10.1200/JCO.23.01280). Matches c005/c011 framing.
- Walsh 2006 fluoxetine-in-AN negative trial: **CONFIRMED** (PMID 16772625, JAMA 295:2605).

**c012 — protein / leucine / arginine**

- **Morton 2018 meta-analysis 1.62 g/kg plateau for FFM gains: CONFIRMED.** Independent retrieval (PMID 28698222, Br J Sports Med 52:376; 49 studies, 1863 participants): "protein intakes at amounts greater than ~1.6 g/kg/day do not further contribute to RET-induced gains in fat-free mass." Exact figure matches.
- Schoenfeld & Aragon 2018 protein distribution (~0.4 g/kg × 4 meals): **CONFIRMED** (PMC5828430, J Int Soc Sports Nutr 15:10).
- Leucine threshold 2.5–3 g young / 3–4 g older: **CONFIRMED** (Moore 2014, Churchward-Venne 2012 anabolic-resistance data).
- Arginine weak evidence for hypertrophy: **CONFIRMED** (Viribay 2020 meta-analysis).

**c013 — creatine / mass gainers / GOMAD**

- Creatine monohydrate ~1 kg lean + 1–2 kg water: **CONFIRMED**. ISSN position stand (Kreider 2017, PMID 28615996) and multiple meta-analyses support +1.0–1.1 kg LBM advantage vs placebo + resistance training. Loading phase 20 g/d × 5–7 days raises TBW by ~1–2 kg. Matches claim.
- Mass-gainer macro breakdown (700–1250 kcal, maltodextrin+whey backbone): **CONFIRMED** via commercial product labels (Serious Mass 1250 kcal, Nutricost 1220 kcal). Descriptive not inferential; good.
- Apetamin FDA / CBP action: **CONFIRMED**. FDA consumer warning page and CBP Baltimore seizure press release both retrievable. The Apetamin / OTC-cyproheptadine hepatotoxicity case reports (e.g., PMC11491866 per claim; PMID 30825493) also check out.
- GOMAD ~2400 kcal / ~128 g protein: **CONFIRMED via standard milk macros** (150 kcal × 16 cups ≈ 2400 kcal). Arithmetic checks.

**c014 — upcycle framing for MtF**

- Elbers 1999 + ENIGI 2017 + JCEM 2022 HRT redistribution to gluteofemoral depots over 12 months: **CONFIRMED directionally**. PMID 29183889 (Klaver 2018 ENIGI) documents fat-redistribution patterns on HRT matching claim.
- Spalding 2008 adipocyte turnover ~10%/year, ~8.3 year half-life: **CONFIRMED** (PMID 18272894, Nature 453:783). Numbers match.
- Karastergiou 2012 sex-dimorphism adipocyte biology (LPL higher in gluteofemoral, estradiol-specific ASC differentiation): **CONFIRMED** (PMC3411490).
- "No peer-reviewed evidence for MtF weight cycling accelerating redistribution beyond HRT alone" — **CONFIRMED UNVERIFIED** (correctly tagged as such). Negative finding; appropriate C4.

**c015 — low-value hype and dangerous**

- **Van Wagoner 2017 JAMA SARMs 44 products analysis: CONFIRMED with nuance.** Independent retrieval (PMID 29183075, JAMA 318:2004): 52% (23/44) contained a SARM; 39% contained a different unapproved drug; 25% contained substances not listed on label; 9% (4/44) contained no active substance; **59% contained substance amounts that differed from the label**. The c015 wording is accurate. The _summary.md phrasing "~59% contamination rate" is slightly imprecise — 59% refers to label-amount-discordance, not "contamination" per se (the contamination-or-wrong-compound figure is closer to 39%+25% depending on how you count). Minor framing refinement rather than an error.
- Insulin bodybuilding hypoglycemia case-report literature: **CONFIRMED** (Evans & Lynch 2003; Dawson & Harrison 1997; J Emerg Med 2019 PMID 30527564).
- DNP 62 fatalities + ongoing deaths: **CONFIRMED** (Grundlingh 2011 J Med Toxicol, PMID 21739343; Holborow 2016 Holborow 2020 updates track ongoing fatality count).
- Clenbuterol myocarditis case reports: **CONFIRMED** (PMC7473675 case retrieves).

### Systematic biases observed

Biases appear MINOR relative to earlier first-wave passes. Patterns observed:

1. **Slight citation-precision issues, not accuracy issues.** Several trials have their effect sizes quoted correctly but the trial-design details simplified. Example: Hunter 2021 cited as "× 28 days" when it's actually an 8-week mirtazapine trial with day-28 primary endpoint; Attia 2019's absolute kg figures (6.7 vs 4.2 kg) are plausible but the published primary endpoint is BMI-rate-per-month, not absolute weight. These are tightening-precision edits, not correctness problems.

2. **Conservative framing is evidence-correct.** The claim files systematically deflate gym/forum narratives (MK-677 is mostly water; tesamorelin reduces visceral fat not bulks; nuts don't proportionally cause weight gain; topical volufiline has no independent RCT). This direction of framing is supported by the literature. No "optimistic framing" bias detected — if anything, the bias is mildly skeptical, which is appropriate for a high-stakes pharmacology topic.

3. **Population-distinction discipline is excellent.** c004, c005, c006, c009, c011 all explicitly flag that effect sizes are from cachexia / FTT / AN populations and do not transfer to healthy bulkers. This is exactly the discipline needed; it avoids the common blog-post failure mode of "megestrol causes +5 kg → megestrol bulks."

4. **Manufacturer-sourced claims correctly tagged.** The Adifyline / volufiline / Sederma brochure data are correctly labeled as manufacturer-sourced (C3 / C4) with explicit "no independent RCT" statements. No laundering of marketing claims.

5. **Cross-reference to prior flagged risks was addressed.** The Svensson 1998 / Murphy 2001 conflation flagged in the earlier review was correctly resolved in c006; the Bhasin 1996 numbers in c008 are accurate to the primary source.

### Corrections needed

Priority-ordered, specific edits suggested (reviewer did NOT edit files):

1. **c004 cyproheptadine/mirtazapine — Hunter 2021 trial duration.** Current wording: "mirtazapine 15 mg nightly × 28 days". More accurate: "mirtazapine 15 mg nightly × 8 weeks with day-28 primary appetite endpoint". Minor precision fix.

2. **c005 megestrol/dronabinol/olanzapine — Attia 2019 absolute weight figures.** Current wording: "about 6.7 kg vs 4.2 kg, BMI rate-of-change 0.259 vs 0.095 BMI units/month". Recommend dropping the kg figures (they are not the published primary endpoint numbers and may be derived/secondary) and retaining the BMI-rate figures which are correct and directly sourced. Suggested rephrase: "significantly greater BMI rate of change (0.259 vs 0.095 BMI units/month; equivalent to ~1 lb/month more for a 5'5" woman), with no significant benefit on eating-disorder psychopathology."

3. **c010 topical local adipogenesis — Volufiline breast-volume number.** Current wording: "~6.5% breast volume increase over 2 months at 2% product". Sederma materials cite different percentages at different product concentrations and application conditions (e.g., ~2.2% at 5% Volufiline in one brochure iteration). Suggest: "Sederma brochures report breast/cheek volume increases ranging from ~2% to ~6.5% depending on product concentration (2–5%) and application duration (4–8 weeks); all data is manufacturer-run and not independently replicated." This preserves the skeptical direction while not pinning a specific number to an unstable source.

4. **_summary.md — SARM contamination phrasing.** Current wording in takeaway 7: "JAMA 2017 found ~59% contamination rate across 44 products". More precise per Van Wagoner 2017: "only 52% of 44 products contained a SARM; 39% contained a different unapproved drug; 9% contained no active compound; 59% had actual-dose-vs-label discordance." Current phrasing conflates "contamination" with "dose-mismatch"; both are bad but they are different findings.

5. **c006 MK-677 — Adunsky cross-verification flag.** The claim file marks Adunsky cross-verified=no because the primary was not directly retrieved in the original pass. Independent retrieval in this audit did retrieve the primary (PMID 21067829) and confirmed 6.5% vs 1.7% CHF. Suggest flipping cross-verified to yes.

6. **Scope gap note (not a correction):** _summary.md refers to c017 (antipsychotics class effect) and c019 (hormonal contraceptives) which exist in the claims folder but were NOT in this audit's scope (audit was limited to c001–c015 as briefed). If those files feed into the framing, consider adding them to the next verification pass.

### Notes on areas NOT flagged as risky but checked anyway

- Creatine effect size (c013): clean match to ISSN + 2024 dose-response meta-analysis.

## 2026-04-18: Hair removal community layer

- `CONFIRMED` The trans-community “laser first, electrolysis second” workflow is not just forum lore; it is corroborated by multiple independent community sources and is directionally consistent with the existing clinical evidence base plus the 2022 pre-vaginoplasty comparison.
- `CONFIRMED` Washington Apple Health and MassHealth currently have explicit, source-verifiable gender-affirming hair-removal coverage language, though community reports still describe serious provider-network friction.
- `PARTIALLY CONFIRMED` Oregon’s community claim that “hair removal is covered in Oregon” needs nuance. Commercial protections are strong under HB 2002, but OHP materials still point more clearly to surgical-site preparation coverage than broad facial-hair coverage.
- `CONFIRMED` New York state guidance and AG materials explicitly include permanent hair removal within medically necessary gender-affirming care categories.
- `CONFIRMED` California DHCS continues to state that medically necessary gender-affirming care remains covered under Medi-Cal, but implementation remains uneven at plan/provider level according to community reports.
- `CONFIRMED` Community complaints about major laser chains are repetitive enough across Reddit, BBB, Yelp/Trustpilot-style aggregators, and business responses to treat the pattern as real: financing pressure, refunds, scheduling drift, and poor continuity are the core failure modes.
- `CONFIRMED` Electrology 3000 is still actively operating in April 2026 based on its live site, but community views of its outcomes are mixed rather than uniformly positive.
- `UNVERIFIED` I did not verify current 2026 practice status for several older named community references from the brief, including Vera Male, Rita Henn & Norma, Lupe’s, and Ginger Chien. These are logged in `tasks/human-tasks.md` and marked as pre-2026/unverified in the new files.
- Bhasin 2001 dose-response design (c008): 25/50/125/300/600 mg × 20 weeks with GnRH-agonist suppression — matches PMID 11701431 exactly.
- Fearon 2011 pre-cachexia / cachexia / refractory staging (c011): matches primary consensus paper wording.
- ROMANA 1/2 LBM numbers (c006): 0.99 / 0.65 kg match Lancet Oncology primary paper to two decimals.
- Bhasin 1996 numbers (c008): flagged-risk area, re-verified — 6.1 kg FFM at 600 mg/wk + training is accurate.

### Highest-priority editable corrections

Only two rise above "precision tightening":

- **c010 Volufiline specific number** — suggest loosening to a range or dropping the specific 6.5% figure to avoid anchoring on one Sederma brochure version.
- **_summary.md SARM "59% contamination" phrasing** — distinguish dose-discordance from compound-misidentification.

Both are framing-level, not ranking-level. The overall takeaway hierarchy (food+training is the big lever; clinical appetite stimulants are cachexia-only; MK-677 is mostly water; tesamorelin reduces visceral fat; androgens oppose feminization; topical local-adipogenesis is not supported) is fully supported by the independent literature and does not change.

## 2026-04-18: Hair styling

- `CONFIRMED` McMullen 2011's counterintuitive result belongs in the summary: moderate-distance blow-drying can produce less surface damage than prolonged uncontrolled air-drying, while close/high heat remains damaging. Cross-check: the PubMed record and secondary summaries match on the practical direction.
- `CONFIRMED` Heat protectants reduce but do not erase thermal damage. Cross-check: the 2011 flat-ironing pretreatment paper and broader hair-cosmetics review both support the "lower damage, not zero damage" framing.
- `CONFIRMED` Tight braids / ponytails / weaves / extensions remain the main styling-to-hair-loss bridge and deserve cross-linking into `research/hair-loss/`. Cross-check: StatPearls traction alopecia and BAD Afro-textured-hair guidance align.

## Hair styling critique 2026-04-18

- `CORRECTED` McMullen 2011 was misframed and partly misattributed. The relevant paper is `Annals of Dermatology` (PMID `22148012`), not `Int J Cosmet Sci`. The revised files now state the actual finding: natural drying caused less surface damage than blow-drying, but prolonged wet time caused more cell-membrane-complex damage; the tested blow-dry condition with continuous motion at `15 cm` performed better overall than the natural-drying condition. Sources: PubMed `22148012`, Ann Dermatol PDF.
- `CORRECTED` Rele and Mohile 2003 is now described more precisely as a wash/protein-loss study in `J Cosmet Sci` (PMID `12715094`), not a generic proof that coconut oil is uniquely magic. The revised text now states that coconut oil reduced protein loss in that model and outperformed mineral and sunflower oil there. Source: PubMed `12715094`.
- `CORRECTED` Relaxer/straightener cancer wording is now tied to the actual Sister Study effect sizes. The revised summary and webapp now cite Chang et al. 2022 uterine-cancer estimates of `HR 1.80` for ever use and `HR 2.55` for frequent use `>4` times/year, instead of looser wording. Sources: JNCI article/PubMed `36245087`, NIH release.
- `CORRECTED` The follow-up timeline on relaxer-related cancer signals is now explicit. The updated copy distinguishes the Sister Study breast-cancer report from `2019`, ovarian follow-up from `2021`, uterine from `2022`, and non-reproductive follow-up from `2025`, instead of blurring them together. Sources: NIH 2019 release, PubMed `34173819`, PubMed `41022397`.
- `CORRECTED` OSHA formaldehyde limits and salon-exposure language were tightened. The revised files now state `0.75 ppm` as the 8-hour TWA and `2 ppm` as the 15-minute STEL, and note that OSHA salon monitoring plus Pierce et al. 2011 found STEL exceedances in some smoothing-treatment conditions. Sources: OSHA formaldehyde standard, OSHA salon page, PubMed `22035353`.
- `CORRECTED` IARC formaldehyde language is now specific rather than vague. The webapp and summary now identify formaldehyde as `Group 1` carcinogenic to humans and name nasopharyngeal cancer and leukemia, particularly myeloid leukemia, as the clearest cancer associations. Source: NCI formaldehyde fact sheet summarizing IARC/NCI evidence.
- `CORRECTED` Bond-builder claims were downgraded. The revised files now identify Olaplex's active as `bis-aminopropyl diglycol dimaleate` but explicitly state that independent clinical data for consumer products such as `Olaplex No.3` and `K18` are limited relative to the marketing. Sources: Olaplex safety page, ACS C&EN overview.
- `CORRECTED` Heat-temperature tables are now hedged as practitioner/manufacturer heuristics rather than evidence-based medical thresholds. The webapp no longer presents `fine hair 300-330 F` and similar ranges as if they were directly trial-backed. Sources: Dyson Corrale guidance, Color Wow Dream Coat instructions, general hair-fiber literature.
- `CORRECTED` Traction-alopecia terminology is now more accurate. The revised files explicitly use `fringe sign`, replace Norwood/Ludwig-style staging with `M-TAS`, and state that late-stage disease can become cicatricial/scarring and not fully recoverable. Sources: PubMed `22136857`, StatPearls traction alopecia.
- `CORRECTED` Wig-adhesive language is now more honest about evidence quality. The revised files keep allergic contact dermatitis as well-supported, but now describe folliculitis/occlusion risk from `Got2b` scalp use as clinically plausible with thinner direct literature rather than established brand-specific evidence. Sources: hair prosthetics review, scalp ACD review, community reports.
- `CORRECTED` Trans HRT curl-pattern change is now explicitly tagged as `C4-community`. The revised research and webapp no longer present a `1-3 year` curl-shift timeline as if it were published trans-specific evidence. Source: GAHT hair-growth systematic review plus community threads.
- `CORRECTED` Dry-shampoo scalp caveats were softened. The revised product table and webapp now state that the buildup/folliculitis warning is mostly expert opinion and anecdote rather than a strong controlled evidence base. Sources: Dermatology Times commentary and lack of stronger primary trials located in this pass.
- `CORRECTED` Cross-links to hair-loss medications now use defensible dosing language. The revised trans-specific file and webapp identify finasteride `1 mg`, dutasteride `0.5 mg`, and low-dose oral minoxidil often around `2.5-5 mg` as common AGA-literature doses, while explicitly noting that response is variable and usually partial. Sources: FDA finasteride label, Endotext AGA review.
- `CORRECTED` Chelating-wash claims were narrowed. The revised wash/prep and summary files now distinguish between stronger evidence that hard water deposits minerals on hair and weaker direct evidence for the performance of specific chelating shampoos, while retaining EDTA/phytic-acid logic as reasonable practice. Sources: PubMed `28799530`, JAMA Dermatology EDTA hair-rinse paper.
- `CORRECTED` Spot-check price updates were applied where stale. `Dyson Supersonic Nural` was updated from `$499.99` to current official listings around `$449.99`; `Revlon One-Step Volumizer` was tightened from `$40-70` to about `$40-50`; `Batiste Original` was widened to about `$10-13` based on current retailer pricing. Sources: Dyson US, Ulta, Target.

## Skin texture critique 2026-04-18

- `CORRECTED` The enlarged-pore copy no longer attributes a precise tretinoin pore-size reduction percentage to `Kang 2005`. Cross-check: the Sewon Kang facial-photodamage trials support tretinoin for photoaging, but not the internet-standard "22-25% pore shrinkage" claim; that exact style of pore-number language is better tied to later small imaging studies and should not be presented as Kang's result.
- `CORRECTED` The isotretinoin timing language is now narrower. Cross-check: the 2017 ASDS consensus supports no mandatory delay for superficial chemical peels and non-ablative lasers/lights, not a universal green light for every resurfacing procedure. Deep dermabrasion and fully ablative resurfacing remain separate caution categories.
- `CORRECTED` The Fitz V-VI framing now treats RF microneedling and conservative microneedling as practical lower-PIH options without claiming they are categorically superior to all fractional-laser approaches. Cross-check: 2023-2025 acne-scar/systematic-review literature supports a safety advantage in practice, but heterogeneity is too high for a blanket `RFMN > fractional laser` rule.
- `CORRECTED` Bellafill wording now states the acne-scar FDA approval date correctly as `December 23, 2014` and stops implying that a dedicated five-year acne-scar RCT underlies the indication. Cross-check: FDA PMA supplement `P020012/S009` plus the pivotal PMMA-collagen acne-scar trial support controlled efficacy through 12 months; longer-duration language is broader PMMA/Bellafill durability data, not a five-year acne-scar endpoint.
- `CORRECTED` TCA CROSS wording now specifies focal scar-only application, `65-100%` literature concentrations, and a typical `3-6` session course spaced about `4-8 weeks` apart. Cross-check: acne-scar reviews and primary studies support these ranges but do not justify a single universal improvement percentage, so the stronger internet numbers were avoided.
- `CORRECTED` RF microneedling device copy now uses manufacturer/FDA-confirmed device ranges instead of brochure-style pseudo-prescriptive settings. Cross-check: Morpheus8 FDA documentation confirms tip-specific depths from fixed `0.5 mm` up to `7 mm`; Vivace official treatment guides describe roughly `0.5-3.5 mm`; published Genius studies remain less standardized in protocol reporting than the marketing suggests.
- `CORRECTED` Rosacea vascular-device wording now distinguishes persistent erythema/telangiectasia from papules/pustules. Cross-check: 2024 rosacea vessel-targeting reviews and 2024 IPL/PDL meta-analyses support PDL/IPL/KTP for erythema and telangiectasia; papulopustular disease still relies primarily on medical anti-inflammatory therapy.
- `CORRECTED` Collagen-drink copy now names the evidentiary weakness more directly. Cross-check: `Choi 2014`, `Proksch 2014`, and `Bolke 2019` support at most small short-term instrumental changes in an industry-linked literature base; the 2025 meta-analysis reported no benefit in non-industry-funded subgroup analyses.
- `CORRECTED` The hype section now avoids dismissing niacinamide along with purely optical pore products. Cross-check: niacinamide has a modest clinical literature base for sebum and pore appearance and should be treated as a helper, not lumped with silica-primer theater.
- `CORRECTED` Subcision wording now treats the evidence as supportive but not pristine and avoids overselling it as if supported by stronger comparative evidence than actually exists. Cross-check: Alam et al. 2005 remains a key rolling-scar study, but the level-of-evidence claim was softened.
- `CORRECTED` KP and rough-body-texture copy now uses a more defensible concentration range: routine maintenance language centers on urea `10-20%`, while acknowledging that higher-strength `30-40%` and sometimes `50%` products exist but are more keratolytic. `AmLactin` is correctly identified as a `12%` ammonium-lactate benchmark.
- `CORRECTED` The Bellafill card in `webapp/skin-texture.html` incorrectly called Bellafill `CaHA / PMMA`; it now correctly identifies Bellafill as PMMA in bovine collagen carrier.

## 2026-04-18: HRT timing × body maturation

- `CONFIRMED` The core "timing cliffs are system-specific" framing is supported. Cross-check: forensic skeletal maturation, endocrine guidelines, ENIGI body-composition papers, and modern voice literature all point in different closing windows rather than a single age cutoff.
- `CONFIRMED` Medial clavicle maturation is one of the latest well-supported skeletal windows, with substage `3c` first observed at `19` and symmetric stage `4` supporting age `>21` in young men. Cross-check: PMID `26188638` and PMID `38960911` agree on the broad timing.
- `CONFIRMED` Feminizing hormone therapy does not raise pitch; post-puberty voice change requires training and/or surgery. Cross-check: Endocrine Society guideline plus modern voice-feminization meta-analysis and Wendler series align.
- `CONFIRMED` Adult-start feminizing GAHT still changes body composition meaningfully. Cross-check: PMID `27572683` and PMID `34415999` both support substantial fat-gain / lean-mass-loss / VAT-ratio-shift framing.
- `CONFIRMED` Bone-density accrual is temporarily blunted during puberty suppression and generally recovers with later GAH, though transfeminine lumbar spine remains the main residual concern. Cross-check: Klink 2015, Vlot 2017, and long-term follow-up PMCID `PMC10616766` are directionally aligned.
- `CONFIRMED` Skin improvement with estrogen is real and not just anecdotal. Cross-check: Brincat primaries and the 2023 meta-analysis support increased collagen/thickness in hypoestrogenic women receiving hormone therapy.
- `CONFIRMED` Breast growth continues beyond year 1 in adult trans women, but the literature does not support pretending that late-start E2 usually recreates a cis female puberty endpoint. Cross-check: de Blok 2021 supports continued 3-year growth with modest satisfaction.
- `PARTIALLY CONFIRMED` The project brief's claim that androgenic body/face hair keeps recruiting into later adulthood is directionally right, but the standardized quantitative literature is thinner than the AGA or skin literature. Wording in the new files was therefore kept qualitative and cautious.
- `PARTIALLY CONFIRMED` "Ribcage widens more on T after 18" remains only partly verified. The current draft distinguishes better-supported late clavicle/chest maturation from weaker claims of large adult ribcage expansion.
- `UNVERIFIED` I did not retrieve a clean primary-source table giving exact age-stratified dimensions for thyroid, cricoid, arytenoid, and hyoid structures all in one place. The current laryngeal file uses a cautious synthesis from morphometric and anatomy references instead.
- `CONFIRMED` Formaldehyde-releasing keratin/smoothing treatments are a real exposure hazard, not internet exaggeration. Cross-check: OSHA salon monitoring, FDA consumer update, and CIR safety assessment converge.
- `PARTIALLY CONFIRMED` Bond-builders such as Olaplex have plausible chemistry and strong salon uptake, but the independent direct evidence is thinner than marketing implies. Cross-check: brand and chemistry-overview sources support plausibility, while independent community/lab critiques justify staying at C3.
- `PARTIALLY CONFIRMED` Dry shampoo is useful but not scalp-neutral. Cross-check: review sources and dermatology-style guidance support the buildup/irritation framing, but direct controlled scalp-harm trials were not located in this pass.
- `UNVERIFIED` I did not retrieve a strong primary trans-specific styling evidence base beyond community consensus; those recommendations stay explicitly tagged `C4-community`.

### Corrections made

- Corrected the clavicle section and summary to keep the stage-based forensic framing: `stage 3c first at 19` from Ekizoglu et al. and `complete symmetrical stage 4 >21` from Vamberszky & Uhl. Removed the tidy public-facing line "`clavicle fuses at 25`." Sources: PMID `26188638`; PMID `38960911`.
- Corrected the sternum/rib framing by removing the webapp and matrix shorthand "`sternum ~25`." Replaced it with a split between developmental sternebral fusion and highly variable later manubriosternal/xiphisternal fusion. Sources: PMID `24100061`; PMID `30539209`; PMID `4854943`; PMID `34893986`.
- Tightened the voice normative section so the adult cis-male `~107-132 Hz` and cis-female `~189-224 Hz` values are presented as synthesis ranges from classic literature, not falsely pinned to one single study. Sources re-anchored to Stoicheff and Pegoraro-Krook: PMID `7300286`; PMID `3049278`.
- Corrected the prepubertal voice framing by replacing overconfident "`220-260 Hz`" wording with a more defensible `~240 Hz` summary anchored to the pediatric electroglottography study. Source: PMID `7558642`.
- Corrected thyroid-cartilage ossification wording from a tidy "`begins 18-20`" statement to a variable late-adolescent/early-adult onset with lifelong progression. Sources: Hately 1965 DOI `10.1259/0007-1285-38-452-585`; Jurik 1984; later anatomy/radiology reviews.
- Corrected the skin section so Shuster is no longer overstated as a rigid universal rule. Reframed as approximately `1% per year` after early adulthood, usually conveyed through later summaries of the original paper.
- Re-verified Brincat and kept only the supported claims: `48%` higher collagen content in treated vs untreated postmenopausal women in 1983, and prevention/partial restoration framing in 1987. Sources: PMID `6416400`; PMID `3828252`.
- Corrected the sebum section by narrowing Pochi 1977 to what it actually studied: childhood/pubertal lipid changes in acne-prone families. Removed unsupported lifespan-curve precision. Source: PMID `143498`.
- Re-verified Klaver and kept the adult feminizing-GAHT means as means from the meta-analysis: `+1.8 kg` body weight, `+3.0 kg` fat mass, `-2.4 kg` lean mass. Source: PMID `27572683`.
- Re-verified the ENIGI visceral-fat paper and corrected the body-composition file/webapp to `+4.0 kg` total body fat, no significant mean visceral-fat change, and `17%` lower VAT/TBF ratio at 1 year. Source: PMID `34415999`.
- Corrected the Fighera citation usage. The earlier framing implied Fighera 2019 was a primary body-composition cohort; it is a bone systematic review/meta-analysis and is no longer used as a body-composition anchor. Source: PMID `31020058`.
- Re-verified Klink 2015, Vlot 2017, and later blocker/BMD framing. Summary and matrix now distinguish temporary suppression-related accrual deficits from later recovery rather than oversimplifying blockers as neutral or permanently harmful. Sources: PMID `25427144`; PMID `27845262`; PMID `40756711`.
- Corrected the breast-development framing so Hembree 2017 is treated as a guideline summary, not the primary breast-growth dataset. Source: PMID `28945902`.
- Re-verified de Blok 2021 as PMID `33206172` and corrected the file/webapp to the `3-year`, median-age-`26`, `~72 cc` per-breast growth, `~100-101 cc` final-volume framing with early plateau in breast-chest difference. Source: PMID `33206172`.
- Removed the unsupported claim that older initiators have a well-demonstrated higher rate of Tanner `3` ceiling. Replaced with the narrower statement that later initiation often means a lower visible ceiling relative to chest width. Source basis: de Blok 2021 plus lack of strong age-stratified longitudinal Tanner evidence.
- Downgraded myonuclear-retention framing to animal/basic-science plus inferential human relevance rather than treating it as proven long-term transfeminine clinical fact.
- Corrected the fertility section to keep Jiang 2019's histology numbers (`81%` germ cells, `40%` spermatids) and Dabel 2023's suppression findings, while avoiding overconfident reversibility timelines. Sources: PMID `31310772`; PMID `36489201`.
- Removed the unsupported quantitative claim that testicular volume shrinks by about `50%` in `12-24 months`. Replaced with a qualitative, source-defensible expected-clinical-effect statement.
- Removed the unsupported penile-atrophy quantification and kept the literature-tempered formulation that long-term androgen suppression can produce real but variably quantified atrophy.
- Corrected the blockers/vaginoplasty section so "option space" now distinguishes reduced penile/scrotal tissue for classic penile inversion from the availability of alternative techniques such as robotic peritoneal flap vaginoplasty. Sources: PMID `36729740`; PMID `35998270`.
- Removed surgeon-status/medical-tourism name checks from the face file because they were not necessary to the biological argument and would require separate current-status commercial verification.

## HRT timing deepen pass

- Rewrote `research/hrt-timing-body-changes/_summary.md` from a short evidence map into a synthesis essay organized around three reversibility classes: developmental architecture, partially salvageable adult endocrine tissue, and cumulative-exposure systems.
- Rebuilt `research/hrt-timing-body-changes/age-windows-matrix.md` as a nine-band narrative rather than a terse symbol table. Each band now states the typical developmental state, what is still open to hormones alone, what is closing, what is effectively closed, and the practical cost of 1-year / 3-year / 5-year delay.
- Added `research/hrt-timing-body-changes/graphs-and-data.md` as a plotting manifest. It now lists the graphable curves, x/y axes, source cohorts, representative points, inflection points, and caveats.
- Expanded `bone-and-skeleton.md` to center the endocrine biology of fusion. Key additions: aromatase deficiency and estrogen-resistance evidence for estradiol as the closure signal (PMID `8530621`; PMID `8090165`), explicit separation of clavicle staging from shoulder-width myths, and tighter sternum / costal-cartilage language.
- Expanded `laryngeal-cartilage-and-voice.md` into a full anatomy-and-function chapter. Key additions: cartilage types, cover-body vocal-fold histology, life-course F0 framing, and a clearer separation of therapy, glottoplasty, framework surgery, and tracheal shave.
- Expanded `skin-over-time.md` to separate androgen sebum biology from estrogen dermal-collagen biology and to distinguish hormonal aging from photoaging instead of flattening them together.
- Expanded `hair-over-time.md` around follicle-cycle biology, androgen paradox by body site, cumulative-exposure AGA, and the difference between scalp miniaturization and body-hair recruitment.
- Expanded `body-composition.md` around depot-specific adipose biology, muscle biology, adult GAHT effect sizes, strength data, and the need to distinguish bone density from bone shape.
- Expanded `face-soft-tissue-vs-bone.md` around the substrate distinction: what HRT can move in soft tissue versus what remains mostly skeletal and therefore better mapped to FFS.
- Expanded `genital-and-reproductive.md` around HPG-axis suppression, histology, preservation-before-treatment logic, breast growth through 3 years, and the difference between classic penile inversion constraints and newer peritoneal-flap options.
- Rewrote `webapp/hrt-timing.html` to match the deeper research. The page now includes a narrative age/system matrix, quantified examples in every system section, and a dedicated graphs-and-data section instead of a short myth list plus one-line cards.
- Evidence added or tightened in this pass includes: Morishima aromatase deficiency (PMID `8530621`), Smith estrogen resistance (PMID `8090165`), clavicle staging cohorts (PMID `26188638`, PMID `38960911`), pediatric / adult F0 anchors (PMID `7558642`, PMID `7300286`, PMID `3049278`), adult body-composition cohorts (PMID `27572683`, PMID `34415999`, PMID `31794605`), blocker / BMD cohorts (PMID `25427144`, PMID `27845262`, PMID `32832823`), skin collagen evidence (PMID `6416400`, PMID `3828252`), hair review data (PMID `37311161`), orchiectomy histology (PMID `31310772`), spermatogonial-suppression framing (PMID `36489201`), and 3-year breast-volume follow-up (PMID `33206172`).
- Important correction logged: the commonly repeated Morishima aromatase-deficiency citation in community discourse is often misquoted as PMID `7496515`; the verified PubMed record is PMID `8530621`. The rewritten files use the verified PMID.
- Residual uncertainty remains in several areas and is now stated more directly instead of hidden: exact longitudinal penile-dimension trajectories, exact standardized testicular-volume-loss percentages, uniform field-by-field body-hair recruitment curves, and clean quantitative laryngeal morphometry tables that capture all cartilages in one source.

## 2026-04-18: Skin texture pass

- `CONFIRMED` The new folder correctly reuses prior evidence rather than re-deriving it. Cross-check: `_summary.md`, `at-home.md`, and `in-clinic-procedures.md` all explicitly cite the relevant `/workspace/skin-research/` summaries and claims for retinoids, acids, acne scars, procedures, laxity, and anti-hype nutrition claims.
- `CONFIRMED` The master summary includes the required intervention x condition matrix and distinguishes texture subtypes instead of flattening everything into generic "resurfacing."
- `CONFIRMED` Fitz I-III versus IV-VI risk framing is explicit in the master summary and in-clinic procedures page, with PIH risk treated as the main constraint in darker skin rather than a side note.
- `CONFIRMED` The pass includes the required failure modes: tram-track scarring from aggressive microneedling, TCA CROSS burns/scar widening, subcision bruising/hematoma, fractional PIH, and retinoid purge.
- `CONFIRMED` The pass includes the required populations: active acne, isotretinoin users, pregnancy, and trans women on estradiol.
- `CONFIRMED` Cross-links to `research/hair-removal/` were added for strawberry legs / PFB overlap in `_summary.md` and `conditions/strawberry-legs.md`.
- `PARTIALLY CONFIRMED` Current US 2025-26 procedure cost ranges were added throughout `in-clinic-procedures.md`, but they are still representative ranges rather than a formal national price survey. Cross-check: ASPS 2024 procedural statistics PDF plus current 2025-26 clinic menus support the order of magnitude.
- `PARTIALLY CONFIRMED` Enlarged-pore procedural evidence is real but remains small-study and heterogeneous. Cross-check: the RFMN retrospective study and 2024 picosecond alexandrite observational study support cautious, not maximalist, language.
- `PARTIALLY CONFIRMED` Sebaceous-hyperplasia evidence remains one of the weakest threads in the folder. The writeup correctly treats lesion-directed destruction as practical first-line while explicitly downgrading confidence.
- `CONFIRMED` The pass flags hype categories the brief required: pore-minimizing cosmetics without a retinoid/AHA/BHA backbone, peptide-only serums for texture, PRP standalone, and cosmetic collagen drinks.
- `UNVERIFIED` Exact device settings for some branded RF microneedling platforms (`Morpheus8`, `Genius`, `Vivace`) were not standardized across independent sources in this pass. The writeup intentionally avoids fake precision rather than inventing "typical" settings.

## HRT genetics / pharmacogenomics pass (2026-05-06)

- `CONFIRMED` The strongest currently actionable signal is route-sensitive smoking induction rather than a stable germline HRT-response SNP. Cross-checking Jensen `1999` (PMID `10425465`), Girdler `2004` (PMID `14704262`), and Michnovicz `1986` (PMID `3773953`) supports the conclusion that smoking materially lowers oral estradiol exposure and has much less effect on parenteral therapy.
- `CONFIRMED` `SHBG` locus signals are real but modest. Cross-checking Prescott `2012` PLoS One with Ruth `2022` Endocrinology and replication cohorts supports keeping `rs727428` in the “interpretive helper” tier rather than the “dose-setting” tier.
- `CONFIRMED` `CYP19A1` `rs727479` is a real endogenous-estradiol signal, but effect sizes are modest enough that it should not outrank direct lab measurement or smoking/route effects.
- `CONFIRMED` The mechanism claim for `AR` CAG repeat was kept, but its clinical actionability was downgraded. Cross-checking receptor-biology reviews against broader clinical reviews supported the narrower conclusion that longer CAG repeats reduce transactivation in vitro while routine HRT prediction remains unvalidated.
- `PARTIALLY CONFIRMED` `COMT Val158Met` clearly changes enzyme function and has some sex-by-estrogen interaction literature, but the stronger community claim that it predicts estradiol intolerance or dictates HRT dosing was not confirmed.
- `SEARCH GAP` I did not verify a strong direct transfeminine study tying common `PGR`, `KISS1R`, `GNRHR`, `FSHB`, `LHB`, `CYP3A4`, or `CES1` variants to routine feminizing-HRT outcomes. Searches were run, but the conclusion remained evidence gap rather than negative proof.

## FFS pass (2026-05-06)

- `CONFIRMED` The new `research/ffs/_summary.md` and companion files are anchored to load-bearing published claims rather than surgeon marketing. The strongest quantitative anchors are the AI/perception studies (`53% -> 98%` and `48.1% -> 74.1%` female classification), the forehead prevalence range (`79%` / `82%` / `92%` / `93.5%` Type III-heavy cohorts), the FACE-Q regional-satisfaction paper (jawline > nose > forehead/eyebrow), the upper-lip systematic review (`9 studies`, `777 patients`), the prospective chondrolaryngoplasty cohort (`15 patients`, `+8.6/10` VAS, no significant permanent voice change), and the systematic-review complication rate (`5.4%`).
- `CONFIRMED` The summary now states clearly that forehead/upper-third priority is an inference from convergent evidence, not a procedure-isolated RCT fact. This matters because lower-face work can outrank forehead in individual patients with very broad jaws, even if the upper third remains the most sex-diagnostic craniofacial region on average.
- `CORRECTED` I did **not** preserve the common “everyone needs pre-op CT” dogma. Cross-checking showed a real contrary dataset: the `422`-patient Boston cranioplasty series reported no routine imaging, `79%` Type III, and no CSF leaks or cranial complications. The folder now says routine CT is debatable and most justified for revision, trauma, congenital anomaly, sinus disease, or VSP-heavy planning.
- `PARTIALLY CONFIRMED` Hairline management remains mixed rather than settled. I confirmed the rough `~2 cm` advancement literature and the existence of simultaneous-transplant series, but the evidence on simultaneous versus staged transplant quality is still practice-pattern heavy and not well resolved by comparative data.
- `LIMITATION` I did not find a strong direct comparative study of `Korea-style V-line` versus `Western-style mandibular body contouring` on femininity ratings, revision rates, or function. The lower-face files therefore treat that split as a real aesthetic/philosophic difference but not as a settled evidence-based ranking.
- `LIMITATION` I did not find publication-grade surgeon-volume thresholds or comparative revision-rate denominators by named FFS surgeon. The `surgeon-archetype-map.md` file explicitly stays at the archetype level for this reason.
- `SEARCH GAP` Weak or failed search themes included: clean 2024-2026 comparative data on “emerging” FFS surgeons; robust public revision-rate auditing by surgeon volume; and direct comparative evidence on filler vs fat graft vs malar implants in transfeminine patients specifically.

## Voice training pass (2026-05-06)

- `CONFIRMED` `research/voice-training/_summary.md` and the companion chapter set were built around current guideline and review anchors rather than creator lore. The ranking spine now comes from ASHA, UCSF, the `2023` systematic review/meta-analysis, the Quinn intensive-vs-traditional study, the Hawley/Hancock hybrid-study abstract, and the older oral-resonance and formant-biofeedback literature.
- `CONFIRMED` The old internet rule that a transfeminine speaker must target `220 Hz` did not survive cross-checking. Current source convergence is closer to: clearly masculine below roughly `145 Hz`, ambiguous in the mid-band, and more reliably feminine above `180 Hz` when resonance cooperates. The folder now states this explicitly and avoids claiming a single magic number.
- `CONFIRMED` The strongest anti-hype quantitative claim in the folder is now the resonance anchor: cis female formants average about `17-20%` higher than cis male formants. This was cross-checked between the `2023` review and the McAllister/Fant formant-biofeedback framing, and it materially supports prioritizing resonance over pitch-chasing.
- `CONFIRMED` Training-effect-size language was tightened to the actual meta-analytic numbers rather than vague “voice therapy works” claims. The folder now uses the therapy-only gain range of roughly `25-39 Hz` and clearly states that surgery-related approaches produce larger mean F0 gains.
- `CONFIRMED` Delivery-schedule claims were pinned to the prospective `34`-participant Quinn study rather than forum anecdotes. The resulting recommendation is that consistency matters more than whether therapy is compressed into `4` weeks or spread across `12`.
- `CONFIRMED` The app section now distinguishes between `pitch measurement` and `gender judgment`. Cross-checking supports the narrower claim that Voice Tools / Voice Pitch Analyzer can be useful for pitch tracking, while the “gender %” style feedback remains structurally incomplete because it undercaptures resonance, weight, and pragmatics.
- `PARTIALLY CONFIRMED` Hard numeric formant goals such as `F1 ~600+ Hz` and `F2 ~2200+ Hz` were not promoted to formal claim files. The direction of change is well supported, but the evidence base remains too heterogeneous by vowel, language, and speaker to defend universal cutoffs without overclaiming.
- `PARTIALLY CONFIRMED` Jitter/shimmer literature was reviewed but deliberately downgraded in the narrative. The current file states that these measures are too inconsistent to serve as good self-training targets even though they may still matter in pathology workups.
- `SEARCH GAP` Failed or weak-result search themes included: robust clinician-grade evidence for a prescriptive role of `vocal fry` in transfeminine passing; publication-grade current `2026` pricing for private online voice coaching and SLP cash-pay packages; and a stronger direct study validating consumer resonance-tracking apps rather than pitch-tracking apps.

## oral-vs-sublingual-e2 research 2026-05

- `CONFIRMED` The central plasma back-conversion number is real but narrow: Ruder/Loriaux/Lipsett 1972 reports E1S -> E2 transfer factor `0.014`, E1S -> E1 `0.21`, and E1S MCR `157 L/day` (`70-292`). Longcope 1972 independently supports the E1S -> E1 transfer path with `0.15` (`95% CI 0.12-0.18`).
- `CORRECTED` The prior "oral E2 has 15-25% effective bioavailability when E1S is counted" claim was not supported by any located primary PK metric. The files now treat it as `C5` rather than trying to rescue it.
- `PARTIALLY CONFIRMED` E1S half-life `10-12 h` is supported by Kuhl 2005 and Lobo/Cassidenti 1992. I did not locate a strong primary-source basis for extending the usual value to `30 h`.
- `PARTIALLY CONFIRMED` Oral E2 produces high E1S, but absolute E1S concentration estimates vary materially by source and method. The 1 mg oral micronized estradiol SmPC reports E1S Cmax `10.5 ng/mL`, Cmin `2.510 ng/mL`, Cavg `5.280 ng/mL`, while Slater 2001 reports `38.8 ng/mL` after 15 months of 1 mg oral E2 by RIA. Kuhl supports E1S about `200x` E2 during 2 mg EV treatment. Exact 2 mg trough by modern LC-MS/MS remains a gap.
- `CONFIRMED` Sublingual E2 gives higher early E2 exposure than swallowed oral E2. Doll 2022 trans-specific LC-MS/MS PK reports 1 mg SL Cmax `144 pg/mL` vs oral `35 pg/mL`, Tmax `1 h` vs `8 h`, and AUC0-8 `1.8x` oral.
- `PARTIALLY CONFIRMED` Price 1997 was verified for DOI, design, endpoints, and abstract; Kuhl 2005 supplies Price-derived sublingual peak values (`0.25 mg` about `300 pg/mL`, `1 mg` about `450 pg/mL`). The exact Price table values were not directly extracted because the publisher page was inaccessible.
- `CONFIRMED` The direct trans outcome evidence does not support estrone as a feminization/breast-growth target. de Blok/ENIGI found oral E2 raised estrone strongly (`1443 pmol/L` oral vs `200 pmol/L` transdermal at 3 months) but estrone was not associated with 12-month breast development, and oral vs transdermal breast development was not clearly different.
- `CONTRADICTED / UNVERIFIED` The claim that E1S predicts transfeminine breast development better than E2 was not located in primary literature. Current files mark it `C5`.
- `PARTIALLY CONFIRMED` Breast-tissue E2 can exceed plasma substantially in postmenopausal breast-cancer literature (`10-20x` E2, `2-10x` E1 in Geisler review), but normal breast evidence is less supportive of a universal high tissue:plasma ratio. Files now distinguish malignant/postmenopausal tissue from normal breast and trans HRT.
- `CONFIRMED` Assay-method caveats are material. The files flag older RIA/HPLC-RIA E1S and tissue-estrogen values and avoid mixing them uncritically with modern LC-MS/MS results.